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A b str a c t
Non-insulin dependent diabetes mellitus (NIDDM) is a disease characterized by 
hyperglycemia, hyperinsulinemia, insulin resistance and p cell dysfunction. Recently, 
hyperinsulinemia has been shown to increase insulin resistance through a mechanism 
that involves serine phosphorylation of insulin receptor substrate 1 (IRS-1). Since the 
cytokine receptor associated Janus kinases (JAKs) JAK1, JAK2, JAK3 and Tyk2 also 
tyrosine phosphorylate IRS-1 in response to receptor/ligand binding, IRS-1 serine 
phosphorylation may also counter-regulate cytokine signaling. While much progress 
has been made in delineating the importance of serine phosphorylation within the 
insulin signaling system, it is not known whether IRS-1 serine phosphorylation affects 
cytokine signaling. In addition, the counter-regulatory kinases involved in IRS-1 serine 
phosphorylation remain undefined.
The data in this thesis demonstrate that phosphatidylinositol 3’-kinase (PI 3- 
kinase) associates with a novel serine kinase that can phosphorylate IRS-1 and reduce 
its ability to act as a substrate for insulin and interferon a (IFNa) receptors. PI 3-kinase 
is shown to associate with a wortmannin insensitive 76 kDa serine phosphoprotein 
(pp76) distinct from the p85 subunit of PI 3-kinase. pp76 is phosphorylated by an 
okadaic acid sensitive, PI 3-kinase associated serine kinase (PAS kinase) with 
biochemical properties that distinguish it from the intrinsic serine kinase activity of PI 3- 
kinase and evidence suggests that PAS kinase may be pp76. PAS kinase associates 
with the p85 subunit of PI 3-kinase through src homology 2 (SH2) domain interactions 
and can serine phosphorylate IRS-1 after insulin stimulation. More importantly, PAS
iii
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kinase mediated IRS-1 serine phosphorylation reduced subsequent tyrosine 
phosphorylation of IRS-1 by insulin receptors (IRs). Finally, under hyperinsulinemic 
conditions, IRS-1 serine phosphorylation by PAS kinase can reduce IFNa mediated 
IRS-1 tyrosine phosphorylation. Taken together, these data show that PAS kinase is 
an IRS-1 serine kinase and that PAS kinase may counter-regulate insulin and cytokine 
signaling.
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C h a p t e r  1: L it e r a t u r e  R e v ie w
In tr o d u c tio n
Diabetes mellitus (DM) is a disease characterized by defects in carbohydrate 
metabolism that lead to increased glucose production/decreased glucose utilization and 
thus to hyperglycemia, it is the fourth leading cause of death by disease in the United 
States and accounts for more cases of renal failure, non-traumatic limb amputations, 
blindness, stroke and heart disease than any other malady (1). Although it actually 
represents a broad range of underlying metabolic disorders, DM can be subdivided into 
either type I or insulin dependent DM (IDDM) and type II or non-insulin dependent DM 
(NIDDM). IDDM is thought to primarily result from autoimmune destruction of the 
insulin secreting pancreatic p cells (2). The pathogenesis of NIDDM, however, is more 
complex. Individuals with NIDDM comprise 85 to 90% of persons with DM and are 
identified by the decreased ability of their peripheral tissues to respond to insulin 
(insulin resistance) and by abnormal insulin secretion (P cell dysfunction) (3). 
Hyperinsulinemia and insulin resistance correlate with obesity and are thought to 
precede p cell dysfunction by as much as 10-20 years, but hyperinsulinemia/insulin 
resistance alone does not invariably lead to overt NIDDM (4). However, even in the 
absence of overt diabetes, hyperinsulinemia and insulin resistance can induce other 
metabolic defects. One example of this is syndrome X, where hyperinsulinemia and 
insulin resistance are thought to result in decreased glucose tolerance, increased
1
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hepatic triglyceride synthesis, decreased high density lipoprotein synthesis, increased 
arterial smooth muscle proliferation and increased incidence of atherosclerosis (5).
Recently, hyperinsulinemia has been shown to induce insulin resistance (6-10). 
The mechanism by which hyperinsulinemia induces insulin resistance appears to 
involve increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) leading 
to a decrease in its ability to transduce insulin receptor (IR) signals (7-18). While much 
progress has been made in delineating the importance of IRS-1 serine phosphorylation 
within the insulin signaling system, the serine kinases involved in this process remain 
undefined. Since IRS-1 is also a substrate for interferon a (IFNa), Oncostatin M, 
leukemia inhibitory factor, growth hormone, interleukin-2 (IL-2), IL-4, IL-7, IL-10, and IL- 
15 receptor associated Janus kinases (JAKs) (19-24), hyperinsulinemia may similarly 
lead to dysregulation of cytokine receptor function. Thus, the identification and 
characterization of IRS-1 serine kinases is an important step in elucidating the 
relationship between hyperinsulinemia and insulin/cytokine resistance.
B io l o g ic a l  R o l e  o f  Insulin
Regulation of energy metabolism in mammals is a complex process in which 
hormonal and environmental stimuli are integrated to provide all organs of the body with 
a constant and adequate energy supply. The primary hormone that regulates fuel 
metabolism during times of non-acute glucose need (i.e. the fed state) is insulin, a 5.8 
kDa protein hormone that is produced by the p cells of the pancreas (25). Insulin is first 
synthesized as a 110 amino acid precursor (preproinsulin). During translocation into
i
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the lumen of the rough endoplasmic reticulum (RER), the 24 amino acid signal 
sequence is removed from preproinsulin to create proinsulin (26). The mature insulin 
protein is produced from proinsulin within the p cell secretory granules, where the 31 
amino acid C peptide is removed to yield an A/B heterodimer linked by disulfide bonds 
(26). When blood glucose levels rise, insulin is secreted from the pancreatic p cells in 
two phases. The first phase represents insulin release from the marginated or 
membrane proximal insulin granules and lasts for 5 to 10 minutes (4,27). The second 
phase occurs in response to prolonged increases in blood glucose and represents 
insulin release from more internal secretory granules as well as release of newly 
synthesized insulin (1,27). Once secreted, insulin acts to maintain blood glucose levels 
by inhibiting gluconeogenesis in the liver, stimulating glycogen synthesis and increasing 
glucose transport into liver, muscle and adipose tissues (28). In addition, insulin 
preserves alternate fuel stores by increasing amino acid transport, stimulating protein 
synthesis and inhibiting lipolysis (25).
In su lin  R e sis ta n c e  a n d  N ID D M
In the insulin resistant state, cells no longer respond to normal circulating levels 
of insulin. Insulin resistance is a major feature in the development of NIDDM and is 
associated with hyperlipidema, hypertension, obesity and cardiovascular disease (18). 
The onset of NIDDM is often preceded by a period of increasing insulin resistance and 
hyperinsulinemia (4). Progressive loss of p cell function, possibly due to increased load 
put on the p cells by the increasing insulin resistance, leads to loss of first phase insulin
- i
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
secretion and fasting hyperinsulinemia that is still insufficient to maintain normal blood 
glucose levels, signaling the onset of NIDDM (1). The causes of insulin resistance are 
not fully understood, but they can be grouped into three categories: i) secretion by p 
cells of an abnormal insulin molecule, ii) circulating insulin antagonists or iii) target 
tissue defects in insulin action (29). Perturbations of the IR signaling system are central 
to categories ii and iii above. In addition, recent evidence indicates that in 
hyperinsulinemic states, insulin itself can lead to insulin resistance (6-10). Thus, 
understanding the cellular response to insulin stimulation may lead to new insights into 
the molecular mechanisms of insulin resistance.
T he  Insu lin  R e c e p to r
The cellular effects of insulin are mediated by the IR, a heterotetrameric, 
transmembrane glycoprotein comprised of two a and two p subunits (Figure 1.1) (30). 
The 723 amino acid a subunits and the 620 amino acid p subunits are derived from a 
single pro-receptor precursor by proteolysis (31). The a subunits are responsible for 
insulin binding and are located on the extracellular side of the cytoplasmic membrane 
(30). Alternative splicing of the IR transcript at exon 11 can yield a subunits that differ 
by 12 amino acids (32). While these receptor isoforms differ in insulin binding and 
receptor internalization, the relative physiological role of these isoforms is unclear (31). 
The transmembrane p subunits are linked to the a subunits by disulfide bonds and 
contain an insulin responsive tyrosine kinase domain (30). In the unbound state, the a 
subunits inhibit the intrinsic tyrosine kinase activity of the covalently linked p subunits
4
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(33). Recent crystalographic studies indicate that in the unphosphorylated state the 
hydroxyl group of tyrosine residue 1150 (Y1150) is bound in the kinase active site in an 
orientation that precludes the (3 subunit from binding ATP (34). This suggests a model 
of IR activation where insulin binding to the a subunits induces a conformational change 
in the p subunits that removes Y1150 from the ATP binding site, perhaps in concert 
with its phosphorylation in trans by other IR p subunit (34,35). Once the inhibitory 
influence of the a subunits is removed and Y1150 is phosphorylated, the p subunits 
auto(trans)phosphorylate on Y960, Y1146, Y1151, Y1316 and Y1322 (28).
These sites of IR tyrosine autophosphorylation are functionally divided into three 
categories, the juxtamembrane region (Y960), the regulatory region (Y1146, Y1150 and 
1151), and the C-terminal region (Y1316 and Y1322) (36-42). Y960 is located within an 
NPXY motif. Tyrosine autophosphorylation of the Y960 within this NPXY motif is 
thought to facilitate binding of the IR to IRS-1 and IRS-2 (36-39,43). Additionally, 
replacement of Y960 with alanine reduces receptor internalization, indicating a potential 
role for the NPXY motif in IR recycling (44). Tyrosine autophosphorylation of the 
regulatory Y1146, Y1150 and Y1151 residues stimulates the kinase activity of the IR by 
10-20 fold (40). Interestingly, the role of the C-terminal tyrosine autophosphorylation 
sites Y1316 and Y1322 is less clear, but may involve down-regulating the mitogenic 
properties of the IR. Removal of Y1316/Y1322 by C-terminal deletion or site directed 
mutagnesis results in IRs that exhibit unaltered insulin binding, autophosphorylation, 
receptor endocytosis, IRS-1 phosphorylation and phosphatidylinositol 3 ' kinase (PI 3- 
kinase) activation (42,45,46). However, these mutants display increased sensitivity to
5
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insulin induced mitogenesis, thymidine incorporation, thymidine uptake and S6 kinase 
activation (41,46,47).
Following autophosphorylation, the IR kinase tyrosine phosphorylates 
exogenous intracellular protein substrates. Tyrosine phosphorylated She and IRS-1 
mediate many of the biological effects of insulin by associating with Sre homology 2 
(SH2) domain containing proteins and activating the ras/MAP kinase and PI 3-kinase 
pathways (Figure 1.1) (18,48-50). Phosphorylated She binds to the SH2 domain of 
Grb2 which then binds the ras-activating mSos protein, resulting in activation of the 
MAP kinase cascade (28). Phosphorylated IRS-1 binds and activates PI 3-kinase 
through its SH2 domains (50,51).
In s u lin  R e c e p t o r  S u b s tr a te  1
IRS-1 was initially identified as a 185 kDa phosphoprotein in anti- 
phosphotyrosine blots of insulin stimulated Fao hepatoma cells (52). Analysis of the 
amino acid sequence of IRS-1 reveals an N-terminal domain that shows significant 
sequence homology to a 120 amino acid domain found in pleckstrin (Figure 1.2) 
(49,53). Pleckstrin homology (PH) domains are found in a variety of proteins that are 
involved in cellular signal transduction (54). The exact function of PH domains is still 
unclear, but PH domains appear to assist in association of PH-domain containg 
proteins with cellular membranes by virtue of their ability to associate with lipids (53). In 
IR signaling, the IRS-1 PH (IH1PH) domain is thought to bind the plasma membrane and 
assist in coupling IRS-1 to the IR (43,49,55,56). IR/IRS-1 coupling is also mediated by 
interactions between tyrosine phosphorylated Y960 of the IR (located within an NPXY
6
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motif) and the phosphotyrosine binding ( l ^ 978) domain of IRS-1 protein (36-39). While 
not originally recognized by sequence homology, the crystal structures of IH2PTB and the 
PTB domain of She have identified them as a novel class of PH domain that binds 
phosphotyrosine instead of lipid (53). IRS-1 and She also share another putative 
domain that could potentiate their interaction with the activated IR. This She and IRS-1 
NPXY-binding (SAIN) domain was proposed to explain the abilities of both She and 
IRS-1 to specifically associate with tyrosine phosphorylated NPXY (NPXpY) motifs (57). 
However, while isolated IH2PTB domains bind NPXpY motif containing peptides with high 
affinity, isolated IRS-1 SAIN domains do not (43). Moreover, IRS-1 mutants with SAIN 
domain deletions are phosphorylated with only slightly different insulin dose 
responsiveness as wild type IRS-1 (43). Taken together, these observations suggest 
that the IRS-1 SAIN domain does not assist IRS-1/IR coupling through direct 
SAIN/NPXpY association.
Studies of the effects of mutant IR and IRS-1 molecules on IR signaling have 
been used to delineate the relative importance of the IH1PH and IH2PTB domains. The 
significance of the NPXY/IRS-1 interaction is evidenced by the reduced ability of IR 
mutants with a phenylalanine for tyrosine substitution in the NPXY motif (Y960F) to 
phosphorylate IRS-1 (39). In these studies, IRS-1 overexpression could partially 
compensate for the defect in IRS-1 mediated insulin signaling, indicating that 
IH2PTB/NPXpY interactions are not absolutely essential for the IRS-1/IR interaction (39). 
Interestingly, IRS-1 mutants with either the IH1PH or IH2PTB domain deleted (IRS-1AIH1 or 
IRS-1AIH2, respectively) are not phosphorylated at low insulin concentrations (0.1 - 1
7
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nM), but IRS-1ilH2 is phosphorylated similarly to wild type IRS-1 type at 10-100 nM 
insulin (43,55). However, phosphorylation of both the IRS-1AIH1 and IRS-1 •UH2 mutants 
can be partially rescued by IR over-expression (43,55). Taken together, these data 
suggest that while neither the IH1PH nor the IH2PTB domain is absolutely required for 
IRS-1/IR coupling, in cells with lower IR numbers the IH1PH domain represents the more 
sensitive and essential link between the IR and IRS-1.
Amino acid sequence analysis of IRS-1 also reveals 21 potential tyrosine 
phosphorylation sites and over 30 potential serine/threonine phosphorylation sites (49). 
When phosphorylated on tyrosine residues by the IR kinase, IRS-1 coordinates many of 
the intracellular actions of insulin by binding to the SH2 domain-containing proteins Fyn, 
Grb-2, Nek, SHP2 and PI 3-kinase (18,51,58-63). Since multiple IRS-1 molecules can 
be activated by a single IR, IRS-1 helps not only to amplify IR signals, but also relieves 
the stoichiometric constraints that would be imposed if all of these SH2 domain 
containing proteins were to bind directly to the IR (50). Additionally, IRS-1 associated 
PI 3-kinase is found in Glut4 containing internal membrane fractions, indicating that 
IRS-1 insulin mediated signals have access to subcellular locations that do not contain 
IR (50,64,65). Finally, while IRS-1 was initially identified as a substrate for the IR (49), 
further work has shown that the IGF-1 receptor (66) and the JAK family members JAK1, 
JAK2, JAK3 and Tyk2 (19-24) phosphorylate IRS-1 in response to receptor/ligand 
binding. Thus, in addition to acting as an IR substrate, IRS-1 is also critical for 
intracellular signals transduced by a variety of growth factor and cytokine receptors 
(50).
8
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O t h e r  IR S  Fa m il y  M em b er s
Several proteins with sequence homology to IRS-1 now make up the IRS family. 
IRS-2 was first identified as a 170-190 kDa phosphoprotein that was tyrosine 
phosphorylated in response to both IL-4 and insulin (20,21). Further work has 
demonstrated that IRS-2 can act as an alternative IR substrate in IRS-1 deficient mice 
(67,68). IRS-3 was characterized as a 60 kDa IR substrate (69) that could associate 
with PI 3-kinase (70) and was subsequently sequenced and found to be homologous to 
IRS-1 and IRS-2 (71). IRS-4 was identified as an insulin stimulated 160 kDa tyrosine 
phosphoprotein (72) and later sequenced and found to be another member of the 
growing IRS family (73). Alignment of these IRS sequences reveals that the IRSs 
share several features, including N terminal IH1PH and IH2PTB domains, tyrosine 
residues that serve as SH2 docking sites and serine residues that serve as serine 
kinase phosphorylation sites (50,69,71,73,74). However, while these structural 
similarities have been shown to correlate with some functional similarity, the relative 
role that each of these new IRS family members plays in hormone/cytokine receptor 
signaling is only starting to be understood.
S H 2  D o m a in s
Following insulin stimulation, tyrosine phosphorylated IRS-1 associates with SH2 
domain containing proteins. SH2 domains were first identified as homologous regions 
in Sre family kinases that were required for transforming activity of these kinases (75). 
Since then, SH2 domains have been found in a wide variety of signal transduction 
proteins. These approximately 100 amino acid domains mediate protein-protein
9
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interactions through their ability to bind to phosphotyrosine (pY) residues (76). SH2 
domains bind with very low affinity to isolated pY or pY containing peptides with 
randomized sequences (77). High affinity SH2/pY interactions only occur between a 
specific SH2 domain and pY containing protein/peptide with the appropriate 3 amino 
acid residues on the C-terminal side of the pY (76) (Figure 1.3). For example, the Isl­
and C- terminal SH2 domains of p85 preferentially bind pYXXM motifs on proteins such 
as IRS-1, while the SH2 domains of SHP2 preferentially bind pY - l/V - X - l/V/L/P 
(61,76,77). Thus, the panel of SH2 domain containing proteins that is recruited by a 
tyrosine phosphoprotein such as IRS-1 is determined by the different sequence 
contexts of the pY residues as well as by the availability and sequence specificity of the 
SH2 domains that bind.
PI 3-K in a s e
The best characterized IRS-1/SH2 domain interaction is the one that occurs 
between IRS-1 and PI 3-kinase. PI 3-kinase activation is linked to a diverse group of 
receptor and non-receptor tyrosine kinases (78,79). Insulin stimulated PI 3-kinase 
mediates insulin dependent glucose transport, gluconeogenesis, glycogen synthesis 
and antilipolysis (78). Structurally, PI 3-kinase is a heterodimeric protein composed of a 
110 kDa catalytic subunit (p110) and an 85 kDa regulatory subunit (p85) (Figure 1.4) 
(80-84). The catalytic p110 subunit is a dual specificity lipid and serine kinase 
(78,85,86) that is inhibited by the fungal metabolite wortmannin (87) and the quercetin 
analog LY294002 (88). In the cell, the p110 subunit phosphorylates phosphoinositides 
on the D-3 position of the inositol ring, generating phosphatidylinositol- 3,4-bis and
10
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3,4,5-tris phosphates (82,89-91). These D-3 phosphoinositides are thought to mediate 
the pleotropic actions of PI 3-kinase, including promotion of cell growth, regulation of 
cell differentiation and control of cell metabolism (79). Additionally, p110 has a 
wortmannin and LY294002 sensitive serine kinase activity that can phosphorylate the 
p85 subunit and IRS-1 (85,86,92-94). However, the in vivo significance of p110 serine 
kinase is still uncertain.
The regulatory p85 subunit mediates interactions between PI 3-kinase and other 
proteins, modulates the activity of the p110 subunit and allows for subceilular 
redistribution of PI 3-kinase activity (78). As such, p85 contains a number of potential 
sites for protein-protein interaction, including proline rich motifs, SH2 domains, an SH3 
domain, a Bcr homologous domain and a p110 binding domain (81-84,95-97). The 
SH3 domains of Lck, Fyn, Lyn, c-abl and v-src can associate with the p85 proline rich 
sequences, but the functional relevance of this observation is unknown (78). In 
addition, the p85 SH3 domains can also bind these proline rich sequences, leaving 
open the possibility of p85 self-association (96). By homology to the Bcr gene product, 
the p85 Bcr domain could theoretically act to stimulate GTP hydrolysis in the small G 
proteins rho, rac or CDC42, but this has not yet been demonstrated. While little is 
known about the functional significance of the proline rich, SH3 and Bcr domains of 
p85, the interaction between the SH2 and p110 binding domains of p85 and the p110 
subunit of PI 3-kinase has been studied in detail. When the SH2 domains of p85 bind 
pYXXM motifs, a conformational change occurs that relieves the inhibitory influence of 
the p85 subunit on the p110 subunit, resulting in PI 3-kinase activation (51,98). This 
activation is maximized when both the N- and C- terminal SH2 domains are occupied
11
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by pYXXM motifs (99). In addition to being activated by IRS-1 binding to the p85 
subunit, the p110 subunit may also be activated by association with Ras (79). During 
insulin stimulation, the association of the p85 SH2 domains with tyrosine 
phosphorylated IRS-1 causes PI 3-kinase to move from cytosolic to low density 
microsome/plasma membrane fractions (58,59,63-65). This subcellular redistribution of 
PI 3-kinase is thought to allow PI 3-kinase greater access to its lipid substrates (78).
B io l o g ic a l  r o le  o f  IFNs
IFNs were first identified by their ability to interfere with viral replication in tissue 
culture (100). The IFNs have since been divided into two groups, the type I IFNs that 
include at least 18 subtypes of IFNa, one subtype of IFNp and one subtype of IFNro 
and the type II IFNs that are comprised of one subtype of IFNy (101). In vivo, the type I 
IFNs are produced by virally infected cells, probably in response to double-stranded 
viral RNA, and act to block the spread of viruses to uninfected cells (102). One of the 
primary mechanisms by which the type I IFNs produce resistance to viral replication is 
by inducing the expression of a variety of anti-viral cellular proteins (103,104). These 
proteins include oligo-adenylate synthase, an enzyme that produces 2’-5’ linked ATP 
oligamers and activates an endoribonuclease that degrades viral RNAs and protein 
kinase R (PKR), a PSK that phosphorylates eukaryotic initiation factor-2 (elF-2) and 
inhibits translational initiation (105). In addition to inhibiting viral replication, type I IFNs 
increase antigen presentation to CD8 T cells by increasing expression of MHC class I 
molecules, the TAP transporter proteins and the Lmp2/Lmp7 components of the
12
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proteosome (106). Finally type I IFNs act to increase the killing activity of natural killer 
(NK) cells by 20-100 fold (107).
IFN R e c e p t o r  S ig n a l  T r a n sd u c tio n
The biological effects of the type I IFNs are mediated by the type I IFN receptor 
(IFNaR), a multimeric receptor consisting of at least two subunits, a and p (Figure 
1.5) (108). The type I and type II IFN receptors, along wrLh the IL-10 receptor, comprise 
the class II cytokine receptor family (109,110). Unlike the class I cytokine receptor 
family where receptors share a common transmembrane signaling subunit, the class II 
receptor family members have multiple unique subunits (111-116). In contrast to the 
IR, both class I and II cytokine receptor subunits exist as monomers in the absence of 
cytokine stimulation (111-116). Additionally, these receptors lack intrinsic tyrosine 
kinase activity. Instead, ligand binding induces receptor oligamerization and activation 
of members of the janus kinase family (JAK) of receptor associated tyrosine kinases 
(109,117-122). JAKs associate with receptors through interactions between unique but 
homologous motifs located in the N-terminal half of the kinase and specific sequences 
located in the juxtamembrane regions of the receptor (123). Thus, the specificity of 
binding sequences present in the receptor subunits for particular JAKs determines 
which JAK family members are activated by different cytokine receptors (124).
In the case of the IFNaR, the a subunit and p subunit constitutively associate 
with the JAK kinase family members Tyk2 and JAK1, respectively and are required for 
IFNa binding (112,114-116,125-128). Binding of type I IFNs leads to IFNaR a/p
13
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oligamerization and stimulates JAK1/Tyk2 tyrosine phosphorylation/activation 
(108,112,114-116,126-129) (Figure 1.5). While not fully understood, it seems likely that 
receptor oligamerization leads to an increase in local JAK concentration, possibly to 
ligand induced conformational changes and finally to JAK auto(trans)phosphorylation 
(123). Interestingly, in mutant cell lines lacking either Tyk2 or JAK1, IFNa does not bind 
IFNaR and fails to stimulate tyrosine phosphorylation of the remaining JAK 
(125,127,130). In addition, kinase deficient forms of both JAK1 and Tyk2 act in a 
dominant negative manner to inhibit IFNaR signaling (130,131). However, cells 
transfected with kinase deficient Tyk2 can promote some residual IFN signaling, but 
cells transfected with kinase deficient JAK1 do not retain any IFNaR signaling 
(130,131). Moreover, in cells lacking endogenous Tyk2, the regulatory loop of kinase 
deficient Tyk2 is still phosphorylated in an IFN dependent manner, probably by JAK1 
(132). These results suggest that in type I IFN signaling, JAK1 activation may be 
upstream of Tyk2 activation and that Tyk2 may function as a signal amplifier (123).
Following activation, the JAK/receptor complex mediates tyrosine 
phosphorylation of the IFNaR itself and exogenous intracellular protein substrates, 
including STAT (signal transducers and activators of transcription) family members 
STAT1, STAT2, STAT3, as well as IRS-1 and IRS-2 (22-24,124). STAT2 associates 
directly with tyrosine phosphorylated IFNaR through its SH2 domain, becomes tyrosine 
phosphorylated by Tyk2 and then serves as a docking site for the SH2 domain of 
STAT1 (133). . Upon tyrosine phosphorylation, STAT proteins form homo- and hetero­
dimers that activate transcription of type I IFN sensitive genes (124). In addition to
14
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being recruited as a transcription factor by activated IFNaR, tyrosine phosphorylated 
STAT3 may also act as a docking protein for PI 3-kinase, although the physiologic 
significance of this observation has not been determined (134).
IF N a  M ed ia ted  IRS P h o s p h o r y la tio n
In addition to acting as IR substrates, IRS-1 and IRS-2 (IRS-1/2) are tyrosine 
phosphorylated in response to IFNa stimulation (22-24). IRS-1 and IRS-2 undergo 
rapid tyrosine phosphorylation in response to IFNa stimulation (22,23) and this 
phosphorylation is dependent on Tyk2/JAK1 activation (24). The exact sites of IRS-1/2 
phosphorylation by IFNaR are not known. However, IFNa mediated IRS-1/2 tyrosine 
phosphorylation results in recruitment/activation of PI 3-kinase, but does not result in 
IRS-1/Grb-2 association (135). Thus, common and distinct sites of IRS-1/2 are tyrosine 
phosphorylated by IFNaR and IR.
The mechanism of IRS-1/IFN-aR interaction remains unclear. Insulin, IGF-1 and 
IL-4 receptors contain NPEY motifs that can mediate receptor/IRS-1 interactions 
through its IH2PTB domain (28,37,39,43,57,66,136,137). In contrast, the IFNaR and 
growth hormone receptors do not contain NPXY motifs (50). Recently, Tyk2 was 
shown to associate with IH1PH domains in an IFN-a dependent manner (23). This 
suggests a potential mechanism where IRS-1 might be recruited to the activated IFN- 
aR/Tyk2/JAK1 complex through specific interactions between phosphorylated Tyk2 and 
IH1PH.
15
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Although IRS-1/2 have been clearly established as substrates for the IFNaR, the 
biological role of IRS-1/2 tyrosine phosphorylation in IFN signaling is not known. One 
study to address this point was performed in the murine 32D cell line. These cells 
express neither IRS-1 nor IRS-2, but do express other type I IFN signaling components. 
In this study, IFNa did not increase cell death over 3 days in 32D cells but still mediated 
JAK/STAT phosphorylation (135). However, expression of either IRS-1 or IRS-2 alone 
had no effect on the lack of IFN mediated cell death response of 32D cells to IFNa. 
Thus, IRS-1/2 are not required for JAK/STAT activation and alone are not sufficient to 
signal the anti-proliferative effects of IFNa.
IRS-1 S e r in e  P h o psh o r yla ito n
Serine phosphorylation of IRS-1 is an important mechanism for counter­
regulating the cellular response to insulin (18,50) (Figure 1.6). IRS-1 is phosphorylated 
on serine residues in its basal state and also in response to a variety of hormones and 
cytokines, including insulin itself (11-17,52). Basal serine phosphorylation is thought to 
explain the difference between the predicted molecular weight of 131 kDa and the 
migration of IRS-1 on SDS-PAGE at an apparent molecular weight of 160-185 kDa. 
This basal IRS-1 serine phosphorylation can be greatly increased by okadaic acid (OA), 
a potent inhibitor of type I and 2A phosphatases (11). OA mediated serine 
hyperphosphorylation of IRS-1 has been shown to decrease insulin induced PI 3-kinase 
activation, GLUT4 translocation and insulin-like growth factor II receptor translocation 
(11,138,139). In these studies, the increase in IRS-1 serine phosphorylation correlated
16
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with a decrease in IR mediated IRS-1 tyrosine phosphorylation. Moreover, IR auto­
kinase activity was unchanged by OA treatment and the effect of OA on IR mediated 
IRS-1 tyrosine phosphorylation was reversed by alkaline phosphatase treatment of IRS-
1. Thus, OA mediated serine hyperphosphorylation of IRS-1 can induce insulin 
resistance.
Insulin stimulated IRS-1 serine phosphorylation can also reduce the ability of 
IRS-1 to act as an IR substrate and induce insulin resistance. Chronic hyperinsulinemia 
in animal models induces severe insulin resistance and this effect correlates with 
increased IRS-1 serine phosphorylation as well as decreased IR mediated Glut4 
translocation and IRS-1 tyrosine phosphorylation (7,9,10,18). This phenomenon can 
also be observed in tissue culture, where chronic insulin treatment leads to increased 
IRS-1 serine phosphorylation and decreases in insulin stimulated IRS-1 tyrosine 
phosphorylation, IRS-1 /PI 3-kinase association and Glut4 translocation (8,10,15). One 
potential explanation for this decrease in the ability of IRS-1 to act as an IR substrate is 
that IRS-1 serine phosphorylation stimulated both by OA and insulin reduces the 
binding of IRS-1 to the juxtamembrane (pY960) region of activated IRs (15). In this 
model, serine phosphorylated IRS-1 fails to associate with IRs following insulin 
stimulation and thus cannot be tyrosine phosphorylated.
Studies of the interaction between TNFa and insulin provide further evidence to 
link IRS-1 serine phosphorylation to insulin resistance. TNFa is an inflammatory 
cytokine that is produced by activated macrophages and is thought to mediate many of 
the detrimental manifestations of sepsis and cancer (140,141). However, adipose
17
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tissue can also produce TNFa. TNFa over-production by adipocytes is found in both 
obese rats and humans and correlates with hyperinsulinemia and insulin resistance 
(142-145). This is interesting because insulin resistance and TNFa production are 
common features of sepsis, cancer and obesity. Neutralization of TNFa in obese and 
insulin resistant rats improves insulin sensitivity of peripheral tissues (142,146) and 
administration of TNFa to rats induces insulin resistance in adipose, skeletal muscle 
and liver tissue (147,148). Moreover, obese mice that have targeted null mutations in 
either the TNFa gene or the p55/p75 TNFa receptor genes show significantly increased 
insulin sensitivity (149). The molecular basis for TNFa induced insulin resistance has 
been extensively investigated. TNFa stimulation of adipose, skeletal muscle and liver 
cell lines inhibits IRS-1 and IR tyrosine phosphorylation and also inhibits IRS-1/PI 3- 
kinase association (150-153). TNFa does not increase cellular PTP activity and the 
effects of TNFa on IRS-1 and IR are not abrogated by inhibition of PTPs by vanadate 
(13). However, activation of the TNFa receptor results in increased IRS-1 serine 
phosphorylation (13,14). Thus, TNFa induced insulin resistance correlates with 
increased IRS-1 serine phosphorylation and decreased ability of IRS-1 to act as an IR 
substrate.
One notable difference between these TNFa studies and the studies of OA and 
insulin induced IRS-1 serine phosphorylation is that TNFa mediated IRS-1 serine 
phosphorylation correlates with a decrease in IR auto-kinase activity. The mechanism 
for this appears to involve IRS-1, since TNFa treatment of 32D cells expressing IR 
alone does not lead to decreased IR auto-kinase activity and exposure of 32D cells
18
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expressing both IR and IRS-1 to TNFa does result in a decreased IR auto-kinase 
activity (14). Moreover, an IR auto-kinase inhibitory form of IRS-1 was also observed in 
extracts of adipose and skeletal muscle tissues of obese rats (14). Thus, TNFa 
mediated IRS-1 serine phosphorylation appears to convert IRS-1 into a direct inhibitor 
IR kinase activity. Interestingly, TNFa treatment of Fao hepatoma cells reduces the 
ability of IRS-1 to bind tyrosine phosphorylated IRs (15). Taken together, these data 
indicate that TNFa induces insulin resistance both by decreasing the ability of IRS-1 to 
act as an IR substrate and by converting IRS-1 into an IR kinase inhibitor.
S ites  o f  IRS-1 S e r in e  P h o sph o r yla tio n
Recent efforts to identify IRS-1 serine residues that, when phosphorylated, 
decrease IR-dependent tyrosine phosphorylation of IRS-1 have focused on those in 
close proximity to critical IR phosphorylation sites (10,12,154,155). Replacement of 
serines 612, 632, 662 and 731 with alanine leads to increased insulin-dependent 
tyrosine phosphorylation of IRS-1 and increased PI 3-kinase/IRS-1 association 
(154,155). In addition, phosphorylation of serine 612 by MAP kinase reduces the ability 
of IRS-1 to act as an IR substrate (12,154). Replacement, however, of these pY- 
proximal amino acids with alanine has no effect on okadaic acid-dependent IRS-1 
serine phosphorylation (155). Interestingly, the sites of IRS-1 serine phosphorylation in 
chronic insulin stimulation map to an IRS-1 fragment consisting of amino acids 530-843 
(10). Evidence is also accumulating to suggest that serine phosphorylation within the 
IH2PTB domain may counter-regulate insulin signaling. Recent studies have shown that
19
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the IRS-1 docking protein 14-3-3 binds to phosphoserine 270 (S270) of the IH2PTB 
domain, blocking insulin-dependent tyrosine phosphorylation of IRS-1 and PI 3- 
kinase/IRS-1 association (156,157). Interestingly, okadaic acid and TNFa reduce the 
ability of IRS-1 to interact with the IR NPEY motif (15). This motif is thought to 
coordinate the association of the IR with the IH2PTB domain of IRS-1 (36-39). Thus, 
S270 phosphorylation might allow 14-3-3 binding, masking the IH2PTB domain and 
decreasing the ability of IRS-1 to act as an IR substrate.
P r o s p e c tu s
Although serine phosphorylation of IRS-1 is clearly an important mechanism for 
counter-regulating the cellular response to insulin, the serine kinases that modulate the 
insulin signaling system are poorly defined. Given the role of IRS-1 serine 
phosphorylation in down-regulating insulin signaling and inducing insulin resistance and 
the severity of the potential clinical outcome of insulin resistance, NIDDM, the 
identification and characterization of IRS-1 serine kinases is of critical importance. In 
addition, since both class I and class II cytokine receptors phosphorylate IRS-1 (19-24), 
the isolation of an IRS-1 serine kinase has the potential to provide new insights into the 
molecular mechanisms of cytokine action. Moreover, IRS-1 serine phosphorylation 
provides a potential link between hyperinsulinemia and dysregulation of cytokine 
receptor function. Therefore, the objective of this research project was to identify and 
characterize serine kinases that phosphorylate IRS-1 and counter-regulate insulin and 
cytokine receptor signaling. Here, a novel okadaic acid sensitive, PI 3-kinase
20
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associated serine (PAS) kinase is described. PAS kinase is distinct from the intrinsic 
serine kinase activity of Pi 3-kinase and associates with the p85 subunit of PI 3-kinase 
through SH2 domain interactions (158,159). PAS kinase phsophorylates IRS-1 on 
serine residues after insulin stimulation and reduces the ability of IRS-1 to serve as a IR 
substrate (159). Moreover, under hyperinsulinemic conditions, PAS kinase mediated 
IRS-1 serine phosphorylation can impair JAK mediated IRS-1 tyrosine phosphorylation 
(160). Thus, PAS kinase mediates IRS-1 serine phosphorylation in response to IRS- 
1/PI 3-kinase association and phosphorylates serine residues that are critical to 
counter-regulating insulin and cytokine signaling.
21
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Figure 1.1: IR Signal Transduction
Ligand bound IR autophosphorylates residues Y960, Y1146, Y1150, Y1151, Y1316, Y1322 and then 
phosphorylates IRS-1 and She. Tyrosine phosphorylated She activates the MAP kinase cascade, while IRS-1 
tyrosine phosphorylation activates PI 3-kinase and SHP2.
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Figure 1.2: IRS-1 domain structure
IRS-l/IR association requires IH l1’" (PH) and IH2‘”rH (PTB) domains of IRS-1. The function of the SAIN 
domain is poorly understood. When phosphorylated, Y608, Y638, Y939 and Y9G7 can associate with PI 3-kinase 
(PI3K); residues Y895, Y1172 and Y1222 can associate with SHP2 (SHP); residue Y895 can also associate w ith Fyn 
(Fyn) and Grb-2 (Grb). When phosphorylated by unknown kinase(s), S270 can associate with 14-3-3. 
Phosphorylation of pY proximal residues SG12 (by Erk-1/2), SG32, SGG2 and S731 (by unknown kinase(s)) inhibits 
subsequent IR mediated IRS-1 tyrosine phosphorylation.
10a
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Figure 1.3: SH2 domain specificity
SH2 domains recognize pY in the sequence context of the three amino acid 
residues on the C-terminal side of the pY. Phosphorylated sequences that do not 
match the consensus binding sequence of a particular SH2 domain and non- 
phosphorylated sequences bind with very low affinity.
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Figure 1.4: Domain structure of the p85 and p110 subunits o f PI 3-kinase
A, The p110 catalytic subunit of PI 3-kinase has adapter binding (AB), Ras 
activation (RA), PI 3-kinase homology (PIK) and kinase domains. B, The p85subunit of 
PI 3-kinase has SH3, proline rich (P), Bcr homology (Bcr), p110 binding and N- and C- 
terminal SH2 domains.
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Figure 1.5: IFNaR signaling
A, In the unliganded state, the a and p subunits do not associate with each 
other. The a subunit associates constitutively with Tyk2 while the p subunit associates 
constitutively with JAK1, STAT1 and STAT2. B, Ligand binding promotes receptor 
oligamerization, auto(trans) phosphorylation of JAK1 and Tyk2 and tyrosine 
phosphorylation of the IFNaR. STAT1, STAT2 and STAT3 are tyrosine 
phosphorylated, dimerize and induce transcription from IFNa responsive genes. IRS-1 
and IRS-2 are tyrosine phosphorylated and recruit/activate PI 3-kinase.
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Figure 1.6: IRS-1 serine phosphorylation and IR signaling
IRS-1 serine phosphorylation prior to tyrosine kinase (TK) activation leads to 
decreased IRS-1 tyrosine phosphorylation. IRS-1 serine phosphorylation after TK 
activation counter-regulates the forward TK reaction and may even increase the rate of 
the reverse protein tyrosine phosphatase (PTP) reaction. In either case, increases in 
the activity of IRS-1 serine kinases (SKs) or decreases in the activity of IRS-1 protein 
serine phosphatases (PSPs) leads to decreased IRS-1 tyrosine phosphorylation.
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C h apter  2: P hosphatidylinositol  3 ’-K inase is A ssociated  w ith  a  S erine 
K in a se  that  is A ctivated  b y  O kadaic  A cid
A b s t r a c t
Okadaic acid (OA) is a potent inhibitor of PP1 and PP2A serine/threonine 
phosphatases and an inhibitor of phosphatidylinositol 3’-kinase (PI 3-kinase) 
recruitment/activation. Here we report that PI 3-kinase associates with a serine kinase 
activated by OA. Whole cell phosphorylation studies showed that PI 3-kinase 
associates with a wortmannin insensitive 76 kDa serine phosphoprotein (pp76) distinct 
from the p85 subunit of PI 3-kinase. Serine kinase assays demonstrated that pp76 
phosphorylation was dependent upon a wortmannin insensitive serine kinase contained 
within PI 3-kinase/pp76 complexes and that this kinase had different cation 
requirements than PI 3-kinase serine kinase. Treatment of whole cells with OA lead to 
a wortmannin-independent 7.6-fold increase in pp76 serine phosphorylation and to a 7- 
fold rise in pp76 kinase activity. Together, these findings indicate that pp76 is a PI 3- 
kinase associated phosphoprotein and suggest that pp76 may be a novel PI 3-kinase 
associated serine kinase that is activated by OA.
In tr o d u c tio n
Serine/threonine kinases control a diverse range of intracellular regulatory 
pathways, including glycogen and protein synthesis, calcium transport and cell cycle 
progression (1). Critical to the regulation of these kinases are the serine/threonine
48
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protein phosphatases. These phosphatases can be classified by inhibitor sensitivity 
and substrate specificity as either type-1 phosphatases (PP1) or type-2 phosphatases 
(PP2), with type-2 phosphatases subdivided into spontaneously active (PP2A), calcium- 
dependent (PP2B) and magnesium-dependent (PP2C) classes (2). While molecular 
approaches have identified novel serine/threonine protein phosphatases that do not fit 
the above classification system, PP1 and PP2A are still considered the most important 
phosphatases due to their abundance and broad specificity (1). Okadaic acid (OA), a 
polyether fatty acid isolated from the black sponge Halichondria okadai, is a potent 
inhibitor of both PP1 and PP2A phosphatases (3,4). OA has been a useful tool in 
studying the biologic significance of serine/threonine protein phosphorylation, as 
evidenced by its ability to induce activation of S6 kinase and the mitogen-activated 
protein kinases (MAPKs) (5-8) and to inhibit tyrosine kinase dependent signal 
transduction mediated by phosphatidylinositol 3’-kinase (PI 3-kinase) (9,10).
PI 3-kinase is linked to a diverse group of receptor and non-receptor tyrosine 
kinases (11). Structurally, PI 3-kinase is composed of a 110 kDa catalytic subunit 
(p110) and an 85 kDa regulatory subunit (p85) (12-14). The p110 is a bi-functional lipid 
and serine kinase (15) that is inhibited by the fungal metabolite wortmannin (16). In the 
cell, the p110 phosphorylates phosphoinositides on the D-3 position of the inositol ring, 
generating phosphatidylinositol 3,4 bis and 3,4,5 tris phosphates (13,14,17). These 
phosphoinositides are thought to mediate the pleotropic actions of PI 3-kinase, 
including promotion of cell growth, regulation of cell differentiation and control of cell 
metabolism (18). Additionally, the p110 has protein serine kinase activity that 
phosphorylates the p85 and insulin receptor substrate-1 (IRS-1) in vitro (15,19-22), but
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the in vivo significance of this activity remains unclear. The p85 subunit mediates 
interactions between PI 3-kinase and other cellular proteins (12,18). The p85 binds to 
tyrosine phosphorylated YXXM motifs through its N- and C-terminal SH2 domains, 
changing the subcellular localization of PI 3-kinase and increasing p110 catalytic 
activity (13,23-26). The p85 also contains additional protein-protein interaction sites 
such as proline rich motifs, SH3 and Bcr homology domains (18), but the proteins that 
interact with these sequences are poorly defined. Here we report that PI 3-kinase 
associates with a 76 kDa serine phosphoprotein that is increased in phosphorylation by 
treatment of cells with OA. More importantly, we demonstrate that this PI 3- 
kinase/pp76 complex contains a serine kinase that is activated by OA and distinct from 
the intrinsic serine kinase activity of PI 3-kinase.
M a t e r ia l s  a n d  M eth o d s
Materials- The myeloma cell line U266 was purchased from American Type 
Culture Collection (Rockville, MD). [y32P]-ATP and 32P, were purchased from Amersham 
(Arlington Heights, IL). All antibodies were purchased from Upstate Biotechnology 
(Lake Placid, NY). Cellulose coated thin layer chromatography (TLC) plates were 
purchased from Analtech (Newark, DE). PVDF membrane was purchased from Bio 
Rad (Hercules, Ca). All other reagents and chemicals were purchased from Sigma (ST. 
Louis, MO).
Whole cell phosphorylation- Whole cell phosphorylation studies were performed 
by methods previously described (27). Briefly, U266 cells were serum deprived
50
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
overnight in RPMI 1640 supplemented with 0.1% BSA and then re-suspended in 
phosphate-free RPMI 1640 supplemented with 20 mM HEPES, pH 7.4. Cells were pre­
incubated with either 5 pM wortmannin in DMSO or with DMSO alone for 30 minute at 
37° C and then incubated with 0.75 mCi/ml 32P, for 1.5 hour at 37° C. Cells were 
solubilized in ice cold lysis buffer (1% NP40, 100 mM NaCI, 50 mM NaF, 25 mM 
benzamidine, 1 mM PMSF, 2 pg/ml aprotinin, 2 pg/ml leupeptin, 2 mM sodium 
orthovanadate, 250 nM okadaic acid, 50 mM Tris, pH 7.4) and lysates were 
immuoprecipitated with anti-PI 3-kinase p85 antibody. Resultant immune complexes 
were washed extensively and phosphoproteins resolved under reducing conditions by 
SDS-PAGE on 7-20% gradient gels and examined by autoradiography followed by 
densitometric scanning on a Molecular Dynamics Personal Densitometer (Sunnyvale, 
CA).
Western blotting- Anti-PI 3 <inase p85 immune complexes were prepared as 
above (in the absence of 32P,). Proteins were resolved under reducing conditions by 
SDS-PAGE on 7-20 % gradient gels and electro-transferred to PVDF membrane and 
blotted with PI 3-kinase p85 antiserum. Immunoreactive proteins were visualized by 
secondary detection with [125l]-goat anti-rabbit antibody and autoradiography. Blots 
were analyzed as above.
Phosphoamino acid analysis- Phosphoamino acid analysis was performed as 
previously described (28). Briefly, phosphoproteins were resolved by SDS-PAGE, 
electro-transferred to PVDF membranes and acid hydrolyzed in 6 N constant boiling 
HCI for 2 hour at 110° C. Samples were re-suspended in water, vacuum dried and re­
suspended in running buffer containing 0.3 mg/ml phosphoserine, phosphothreonine
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and phospotyrosine standards. Phosphoamino acids were separated on cellulose 
coated plates by high voltage TLC using a running buffer containing H20:acetic 
acidipyridine, 89:10:1. Results were analyzed by autoradiography on a Molecular 
Dynamics Phosphorimage system (Sunnyvale, CA).
Serine kinase assays- Immune complexes were prepared as above and then 
treated with either 5 pM wortmannin in DMSO or with DMSO alone. Kinase reactions 
were performed in a reaction buffer containing 0.4 mM EGTA, 0.4 mM NaP04, 1 pM 
[y32P]-ATP (100 pCi/nmol), and 20 mM HEPES, pH 7.1 with either 10 mM MnCI2 (Mn(ll)) 
or 10 mM MgCI2 (Mg(ll)) as indicated. Proteins were resolved by SDS-PAGE in 7-20% 
gradient gels and examined by autoradiography and densitometry as above.
R esu lts
PI 3-kinase associates with a 76 kDa serine phosphoprotein distinct from its own 
p85 subunit- The p85 subunit of PI 3-kinase contains protein-protein interaction 
domains that enable the p85 subunit to act as an adapter between itself other proteins 
(18). To examine PI 3-kinase phosphoprotein interactions, whole cell phosphorylation 
studies were performed. Cells were pretreated for 30 minutes with either DMSO or 5 
pM wortmannin in DMSO, labeled with 32P, for 90 minutes and immunoprecipitated with 
either PI 3-kinase p85 antiserum or non-immune serum. SDS-PAGE analysis of the 
resultant immune complexes showed that a 76 kDa phosphoprotein (pp76) associated 
with PI 3-kinase immunoprecipitates and that pp76 phosphorylation was not inhibited by 
wortmannin pretreatment of cells (Figure 2.1 A, left panel). To determine if pp76 had a
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different molecular mass than the p85 subunit of PI 3-kinase, Western analysis was 
performed on samples similar to those generated above (except in the absence of 32P,). 
Figure 2.1 A (right panel) shows that the p85 antibody, when used as a blotting 
antibody, recognized a single band at 85 kDa and did not detect a 76 kDa band. To 
further examine pp76 phosphorylation, phosphoamino acid analysis was performed. 
Figure 2.1 B shows that pp76 isolated from whole cell phosphorylation studies carried 
out in the presence of 5 pM wortmannin was predominately phosphorylated on serine 
residues.
pp76 is phosphorylated by a serine kinase contained in the PI 3-kinase/pp76 
complex- Kinase autophosphorylation is commonly observed with both tyrosine and 
serine kinases (29). To determine if the kinase responsible for pp76 phosphorylation 
was contained in the PI 3-kinase/pp76 complex, serine kinase assays were performed 
on PI 3-kinase and control immunoprecipitates. Figure 2.2A shows that PI 3-kinase 
immunoprecipitates pre-treated for 30 minute with DMSO contained a kinase activity 
that phosphorylates proteins at 76 kDa and 85 kDa (pp85) when Mn(ll) was used as a 
co-factor in the kinase reactions. Pretreatment of immunoprecipitates with 5 pM 
wortmannin in DMSO for 30 minute abolished pp85 phosphorylation but did not reduce 
pp76 phosphorylation. These finding indicate that wortmannin blocked PI 3-kinase 
serine kinase activity (loss of p85 phosphorylation) and that pp76 phosphorylation is 
dependent upon a kinase distinct form PI 3-kinase serine kinase. To confirm these 
results, serine kinase assays were performed as above except 10 mM Mg(ll) was used 
as a co-factor instead of 10 mM Mn(ll) (Figure 2.2A). Previous work has demonstrated 
that PI 3-kinase serine kinase displays a marked cation preference for Mn(ll) over
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Mg(ll) (19,22). In our study, p85 phosphorylation was reduced 10-fold when Mg(ll) was 
used as a co-factor instead of Mn(ll) (Figure 2.2A). In contrast to p85 phosphorylation, 
pp76 phosphorylation did not display a marked cation preference for Mn(ll) over Mg(ll). 
In addition, wortmannin completely abolished Mg(ll)-dependent p85 phosphorylation 
but did not affect pp76 phosphorylation. Phosphoamino acid analysis performed on 
pp76 generated from kinase assays utilizing Mg(ll) and wortmannin treated 
immunoprecipitates demonstrated that pp76 was predominately phosphorylated on 
serine residues (Figure 2.2B).
pp76 phosphorylation and kinase activity are increased by OA- Kinases 
regulated by serine phosphorylation can be activated by phosphatase inhibition (5-8). 
To determine if the kinase activity responsible for pp76 phosphorylation was sensitive to 
phosphatase regulation, whole cell phosphorylation studies were performed on cells 
treated with OA. As in Figure 2.1, cells were pretreated for 30 minutes with 5 pM 
wortmannin in DMSO, labeled with 32P, for 90 minutes and then treated with either 
DMSO or 1 pM OA in DMSO for the final 30 minutes. SDS-PAGE analysis of PI 3- 
kinase immune complexes showed that OA increased pp76 phosphorylation 7.6-fold 
when compared to DMSO treatment (Figure 2.3A). Phosphoamino acid analysis 
demonstrated that this increase in phosphorylation was due entirely to an increase in 
serine phosphorylation (Figure 2.3B). Finally, to determine if pp76 serine kinase activity 
was also increased by OA, serine kinase assays were performed. Cell lysates were 
generated as above (except in the absence of 32P,) and immunoprecipitated with either 
PI 3-kinase anti-serum or non-immune serum. Immunoprecipitates were pre-treated 
with 5 pM wortmannin and serine kinase assays were performed using 10 mM MgCI2 as
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a cofactor. As shown in Figure 2.3C, OA increased pp76 phosphorylation by 7-fold. 
These results indicate that cell-dependent pp76 phosphorylation and phosphorylation of 
pp76 in a cell-free system depends upon an OA activated serine kinase.
D isc ussio n
These data establish that PI 3-kinase associates with a 76 kDa serine 
phosphoprotein (pp76) and a serine kinase that uses pp76 as a substrate. Whole cell 
phosphorylation studies demonstrate that PI 3-kinase co-immunoprecipitates with pp76 
and show that pp76 is neither the p85 subunit of PI 3-kinase nor an in vivo substrate for 
PI 3-kinase serine kinase (Figure 2.1). Phosphorylation of pp76 is dependent upon a 
kinase within the PI 3-kinase/pp76 complex that is distinct from PI 3-kinase serine 
kinase because it is wortmannin insensitive and has different cation requirements than 
PI 3-kinase serine kinase (Figure 2.2). Phosphorylation of pp76 is increased 7.6-fold by 
OA in whole cells (Figure 2.3A.B), but, more importantly, pp76 serine kinase activity is 
increased 7-fold by OA (Figure 2.3C). Taken together, the present results suggest that 
pp76 is a novel PI 3-kinase associated serine kinase with autophosphorylation 
capabilities.
PI 3-kinase is implicated in the activation of serine kinases such as protein 
kinase B (30), pp70 S6 kinase (31) and the novel and atypical protein kinase C (PKC) 
isoforms s, 5, C and r| (32,33). With the exception of PKC 5, none of the above kinases 
are known to associate with PI 3-kinase. PKC 8 is a 70 kDa serine kinase that 
autophosphorylates (34) and associates with PI 3-kinase basally and in response to
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GM-CSF in the erythrocytic leukemia cell line, TF-1 (35). In U266 cells, however, PKC 
5 did not associate with PI 3-kinase by Western analysis (data not shown), nor was 
pp76 phosphorylation inhibited by the PKC 5 inhibitor rottlerin (data not shown). These 
observations indicate that pp76 and pp76 serine kinase are not PKC 5.
OA can activate both S6 kinase (5,6) and MAP kinase family members (MAPKs) 
(5,7,8). While these kinases have not been shown to directly associate with PI 3- 
kinase, they are potential pp76 kinases due to their OA sensitivity. Studies with the S6 
kinase inhibitor rapamycin and the MAPKs inhibitor PD98059 showed that pp76 
phosphorylation was not affected by these compounds (data not shown). These 
observations indicate that S6 and MAPKs are not pp76 kinases. Therefore, we 
conclude from this study that PI 3-kinase associates with a novel 76 kDa serine 
phosphoprotein that is hyperphosphorylated by OA but is neither the p85 subunit of PI 
3-kinase nor a substrate for PI 3-kinase serine kinase. More importantly, we show that 
the PI 3-kinase/pp76 complex contains an OA responsive pp76 serine kinase that may 
itself be pp76.
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Figure 2.1: PI 3-kinase associates with a 76 kDa serine phosphoprotein distinct 
from its own p85 subunit
A, Left Panel, Cells were treated with either DMSO (D) or 5 pM wortmannin (W) 
in DMSO for 30 minute and then incubated in the presence of 32P, for 90 minute. 
Phosphoproteins were immunoprecipitated with either PI 3-kinase antiserum (P) or non- 
immune serum (N) and analyzed by SDS-PAGE. Right Panel, Cells were treated with 
wortmannin and immune complexes generated as above with either PI 3-kinase 
antiserum (P) or non-immune serum (N). Western analysis was performed as 
described in Materials and Methods with anti-PI 3-kinase p85 antibody. B, Whole cell 
phosphorylations were performed as in A , lane 3 and phosphoamino acid analysis of 
pp76 was performed. All data are representative of triplicate experiments.
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Figure 2.2: pp76 is phosphorylated by a serine kinase contained in the PI 3- 
kinase/pp76 complex
A, Immunoprecipitates (IPs) were prepared from cell lysates using either PI 3- 
kinase antiserum (P) or non-immune serum (N). IPs were pretreated for 30 minute with 
either DMSO (D) or 5 pM wortmannin (W) in DMSO and used in kinase assays 
performed in the presence of either 10 mM MnCI2 (Mn(ll)) or 10 mM MgCI2 (Mg(ll)). B, 
Phosphorylated pp76 was generated as in A, lane 7 and phosphoamino acid analysis 
performed on pp76. All data are representative of triplicate experiments.
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Figure 2.3: pp76 phosphorylation and kinase activity are increased by okadaic 
acid
A, Cells were pre-treated with 5 pM wortmannin in DMSO for 30 minutes, 
incubated in the presence of 32P, for 90 minutes and then incubated with either DMSO 
(D) or 1 pM okadaic acid (OA) in DMSO for the final 30 minute. Phosphoproteins were 
immunoprecipitated with PI 3-kinase antiserum and analyzed by SDS-PAGE. B, 
Phosphorylated pp76 was generated as in A, and phosphoamino acid analysis 
performed as described. C, Cells were pre-treated with 5 pM wortmannin in DMSO for 
30 minute and then incubated with either DMSO (D) or 1 pM okadaic acid (O) in DMSO 
for an additional 30 minute. Kinase assays were performed on PI 3-kinase (P) and 
non-immune serum (N) immunprecipitates pretreated with 5 pM wortmannin for 30 
minute using 10 mM MgCI2 as a cofactor. Results were analyzed by SDS-PAGE. All 
data are representative of triplicate experiments.
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C hapter  3: Phosphatidylinositol 3 -K inase A sso c ia tes  with an  Insulin  
Receptor  S ubstrate-1 S erine K inase  D istinct from  its Intrinsic  S erine  
K inase
A b str a c t
Serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been proposed as a 
counter-regulatory mechanism in insulin and cytokine signaling. Here we report that 
IRS-1 is phosphorylated by a wortmannin insensitive phosphatidylinositol 3'-kinase (PI
3-kinase) associated serine kinase (PAS kinase) distinct from PI 3-kinase serine kinase. 
We found that PI 3-kinase immune complexes contain 5-fold more wortmannin 
insensitive serine kinase activity than SHP2 and IRS-1 immune complexes. Affinity 
chromatography of cell lysates with a GST fusion protein to the p85 subunit of PI 3- 
kinase showed that PAS kinase associated with the p85 subunit of PI 3-kinase. This 
interaction required unoccupied SH2 domain(s) but did not require the PI 3-kinase p110 
subunit binding domain. In terms of function, PAS kinase phosphorylated IRS-1 and, 
after insulin stimulation, PAS kinase phosphorylated IRS-1 in PI 3-kinase/IRS-1 
complexes. Phosphopeptide mapping showed that insulin-dependent in vivo sites of 
IRS-1 serine phosphorylation were comparable to those of PAS kinase phosphorylated 
IRS-1. More importantly, PAS kinase-dependent phosphorylation of IRS-1 reduced by
4-fold the ability of IRS-1 to act as an IR substrate. Taken together, these findings 
indicate that: (a) PAS kinase is distinct from the intrinsic serine kinase activity of PI 3- 
kinase, (b) PAS kinase associates with the p85 subunit of PI 3-kinase through SH2
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domain interactions and (c) PAS kinase is an IRS-1 serine kinase that can reduce the 
ability of IRS-1 to serve as an IR substrate.
Introductio n
The insulin receptor substrates (IRSs) are critical for intracellular signals 
transduced by a variety of growth factor and cytokine receptors (1). IRS-1 was 
originally described as the principal substrate for the IR (2), but further work has shown 
that the IGF-1 receptor (3) and the Janus kinase family members JAK1, JAK2, JAK3 
and Tyk2 (4-7) phosphorylate IRS-1 in response to receptor/ligand binding. The 
importance of the IRSs to receptor signaling is that they can amplify receptor signals 
and dissociate receptor signaling from endocytic pathways (1). Molecular analysis of 
IRS-1 shows that it contains multiple protein interaction sites including the N terminal 
IH1PH and IH2PTB domains and 21 potential tyrosine phosphorylation sites (2,8-11). The 
IH1PH domain shows amino acid sequence similarity to the pleckstrin homology (PH) 
domains of Gab1 and DOS (1,11,12) and its deletion from IRS-1 completely inhibits IR- 
dependent signaling through IRS-1 (9-11). The IRS-1 IH2PTB region is a
phosphotyrosine-binding domain (PTB) which interacts with phosphorylated NPXY 
motifs of the insulin, IGF-1 and IL-4 receptors (2,13,14). Substituting phenylalanine for 
tyrosine in insulin and IL-4 receptor NPXY motifs reduces the ability of these receptors 
to phosphorylate IRS-1 (13,14). The tyrosine phosphorylation sites of the IRSs mediate 
their interaction with SH2 domain containing proteins such as Fyn, Grb-2, nek, crk, 
SHP2 and phosphatidylinositol 3' kinase (PI 3-kinase) (1).
The coupling of PI 3-kinase to IRS-1 is the best-characterized SH2
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domain/phosphotyrosine interaction among IRS family members. PI 3-kinase is a 
heterodimeric protein composed of an 85 kDa regulatory subunit (p85) and a 110 kDa 
catalytic subunit (p110) (15). The p85 contains N- and C- terminal SH2 domains that 
bind to tyrosine phosphorylated IRS-1 and induce activation of PI 3-kinase (15-17). 
This activation is maximized when both SH2 domains are occupied by phosphotyrosine 
residues in YMXM motifs (18). The p110 is a dual specificity lipid and serine kinase 
(19,20) that is inhibited by the fungal metabolite wortmannin (15). In the cell, the p110 
phosphorylates phosphoinositides on the D-3 position of the inositol ring generating 
3,4-bis and 3,4,5-tris phosphates (15). Phosphatidylinositol 3,4,5-tris phosphates are 
thought to mediate the pleotropic actions of PI 3-kinase, including promotion of cell 
growth, regulation of cell survival and control of glucose metabolism. The biological 
significance of the p110 serine/threonine kinase is not fully understood, but in vitro it 
can phosphorylate both the p85 and IRS-1 (19-23).
Serine phosphorylation of IRS-1 is developing as an important mechanism by 
which IRS-dependent signal transduction can be inhibited. Treatment of cells with the 
serine phosphatase inhibitor okadaic acid results in increased IRS-1 serine 
phosphorylation, reduced IRS-1/IR binding and decreased IR-dependent tyrosine 
phosphorylation of IRS-1 (24). Similarly, IRS-1 serine phosphorylation induced by 
phorbol esters, TNF-a, PDGF, angiotensin II and insulin reduces subsequent IR- 
dependent IRS-1 tyrosine phosphorylation and PI 3-kinase/IRS-1 association (25-30). 
While serine phosphorylation of IRS-1 has emerged as a critical counter-regulatory 
mechanism in IRS-1 signaling, the serine kinases responsible for IRS-1 phosphorylation
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remain ill defined. We have previously shown that PI 3-kinase co-immunoprecipitates 
with an okadaic acid sensitive serine kinase that is distinct from PI 3-kinase serine 
kinase (31). Here we report that this PI 3-kinase associated serine kinase (PAS 
kinase) associates with the p85 subunit of PI 3-kinase through SH2 domain interactions 
and that this kinase phosphorylates IRS-1 in PI 3-kinase/IRS-1 complexes after insulin 
stimulation. More importantly, we demonstrate that PAS kinase-dependent 
phosphorylation of IRS-1 reduces the ability of IRS-1 to serve as an IR substrate.
M a t e r ia l s  a n d  M eth o d s
Materials- The myeloma cell line U266 was purchased from American Type 
Culture Collection (Rockville, MD). [yP32P]-ATP and 32P, were purchased from 
Amersham (Arlington Heights, IL). PI 3-kinase p85, SHP2, phosphotyrosine (pY) and 
IRS-1 antisera and recombinant rat IRS-1 were purchased from Upstate Biotechnology, 
Inc. (Lake Placid, NY). Neonatal bovine serum (NBS) was purchased from Biocell 
(Rancho Dominguez, CA). [125l]-goat anti-rabbit antibody was purchased from Dupont 
NEN (Wilmington, DE). Protein G-Sepharose, glutathione-Sepharose and pGex4T3 
vector were purchased from Pharmacia Biotech (Uppsala, Sweden). Polyvinylidene 
difluoride membrane (PVDF) was purchased from Bio Rad (Hercules, CA). Cellulose 
coated TLC plates were purchased from Analtech (Newark, DE). The peptides Y608 
(HTDDGYMPMSP) and pY608 (HTDDGpYMPMSP) (17) were synthesized and the 
anti-IR antibody alR-1 was produced from hybridoma by the University of Illinois 
Biotechnology Center (Urbana, Illinois). All other cell culture reagents and chemicals
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were purchased from Sigma (ST. Louis, MO). Oligonucleotide primers were purchased 
from Operon (Almeda, CA). Vent DNA polymerase was purchased from New England 
Biolabs (Beverly, MA). All other molecular biology reagents and chemicals were 
purchased from Promega (Maddison, Wl).
Cell Culture- U266 cells were grown in RPMI 1640 supplemented with 10% NBS, 
2.0 g/L glucose, 100,000 units/L penicillin and 100 mg/L streptomycin. Cells were 
passaged 1:1 with fresh medium every three days. Treatment in serum-free medium 
prior to all studies was performed by washing cells twice and re-suspending cells in 
RPMI 1640 supplemented with 0.1% BSA, 2.0 g/L glucose, 100,000 units/L penicillin 
and 100 mg/L streptomycin at 1x106 cells/ml. All cell counts were performed on a 
Coulter Counter ZM (Hialeah, FL).
Expression Vector Construction- Bovine p85a coding sequence was amplified 
from the p85a plasmid (a kind gift of Michael D. Waterfield) in PCR reaction buffer 
containing 0.1 ng/pl of plasmid template, 500 nM of forward primer (5’- 
GAGGTCCATGAGTGCCGAGGGGTACCA-3’), 500 nM of reverse primer (5’- 
CCGAATT-CTCATCGCCTCTGCTGCGC-3’), 200 pM of each deoxynucleotide 
triphosphate, 0.01 units/pl of Vent DNA polymerase, 2 mM MgCI2, 10 mM KCI, 0.1% 
Triton X-100 and 20 mM Tris, pH 8 .8 . DNA was amplified for 20 cycles in a Stratgene 
RoboCycler (La Jolla, CA) by denaturing for 60 s at 94° C, annealing for 60 s at 55° C 
and extending for 60 s at 72° C. The 2175 bp product was introduced into the pGex4T3 
plasmid using the BamHI and EcoRI restriction sites.
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GST Fusion Protein Isolation- GST, GST-SHP2SH2 (a.a. 1-107 of human SHP2, a 
kind gift of James N. Livingston), GST-Ap85 (human PI 3-kinase p85 with the p110 
binding domain, a.a.479-513, deleted and replaced with SR (32), a kind gift of Masato 
Kasuga), GST-p85 and GST-p85NSH2 (a.a. 333-428 of the human p85a, a kind gift of 
Jonathan M. Backer) proteins were generated as previously described (33). In brief, 
protein expression was induced in E. coli strain BL21 by the addition of isopropyl p-D- 
thiogalactopyranoside to a final concentration of 1 mM. After 4 hour, bacteria were 
lysed in 1 % Triton X-100, 1 mM PMSF, 140 mM NaCI, 2.7 mM KCI, 10 mM Na2 HP04,
1.8 mM KH2 PO4 , pH 7.4 by mild sonication at 4° C. GST fusion proteins were affinity
purified from clarified lysates with glutathione-Sepharose overnight. In all experiments 
where GST proteins were used for affinity chromatography of cell lysates, GST proteins 
were equalized to protein concentration by coomassie staining and used in excess of 
lysate binding capacity.
Kinase Assays- Kinase assays were performed as previously described (31). In 
brief, cells were serum deprived for 18 hour and lysed in ice cold lysis buffer (1% NP40, 
100 mM NaCI, 50 mM NaF, 25 mM benzamidine, 1 mM PMSF, 2 pg/ml aprotinin, 2 
pg/ml leupeptin, 2 mM sodium orthovanadate, 250 nM okadaic acid, 50 mM Tris, pH 
7.4). Immune complexes/GST affinity isolates were generated with the indicated 
antibody or GST fusion protein, washed extensively and treated with 5 pM wortmannin 
for 30 minute at 4° C. Except where noted, kinase reactions were performed in a 
reaction buffer containing 10 mM MgCI2, 0.4 mM EGTA, 0.4 mM NaP04, 1 pM [y32P]- 
ATP (100 pCi/nmol), and 20 mM HEPES, pH 7.1 at RT with the indicated substrate(s)
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for the described times. Reactions were terminated by addition of SDS-PAGE load 
buffer and phosphoproteins resolved by SDS-PAGE under reducing conditions on 7- 
2 0 % gradient gels and examined by autoradiography and densitometry.
Phosphoamino Acid Analysis- Phosphoamino acid analysis was performed as 
previously described (31). In brief, phosphoproteins were resolved by SDS-PAGE on 7- 
20% gradient gels and electro-transferred to PVDF. Bands of interest were excised 
and acid hydrolyzed in 6 N constant boiling HCI for 2 hour at 110° C. Samples were 
treated with 3 cycles of water re-suspension and evaporation then re-suspended in 
H2 0 :acetic acidipyridine (89:10:1) running buffer containing 0.3 mg/ml phosphoserine, 
phosphothreonine and phosphotyrosine standards. Phosphoamino acids were 
separated on cellulose coated plates by high voltage TLC and standards visualized with 
ninhydrine. Results were analyzed by autoradiography on a Molecular Dynamics 
Phosphorimage system (Sunnyvale, CA).
Phosphopeptide Mapping- Phosphopeptide mapping was performed as 
previously described (34). In brief, phosphorylated IRS-1 was obtained (as indicated) 
either by whole cell labeling studies of insulin treated cells or by kinase assays. Whole 
cell labeling studies were performed by incubating cells with 32P, (1 mCi/ml) for 1.5 hour 
in phosphate free media. Thirty minutes prior to insulin treatment (10 nM for 10 minute) 
cells were treated with 5 fiM wortmannin. Phosphorylation of IRS-1 in vitro with PAS 
kinase was performed as described in Kinase Assays. Phosphoproteins were resolved 
under reducing conditions by SDS-PAGE on 8% gels and visualized by 
autoradiography. Gel bands of interest were excised and hydrated in 0.1% SDS, 25%
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glycerol, 5% 2-mercaptoethanol, 0.125 M Tris, pH 6 .8 . In-gel proteolysis with 0.5 units 
of S. aureus V8 protease was performed for 15 minute at RT. 
Phosphoproteins/phosphopeptides were separated under reducing conditions by SDS- 
PAGE on 7-20% gradient gels and visualized by autoradiography. Serine/threonine 
phosphoaminoacids were assessed by their susceptibility to base hydrolysis (35).
Insulin Receptor Isolation and Kinase Assays- Cells were serum deprived 
overnight and lysed in ice-cold lysis buffer. IRs were isolated from clarified lysates with 
protein G-Sepharose bound IR antibody. Resultant immune complexes were washed 4 
times in 0.1% Triton X-100, 50 mM Tris, pH 7.4 at 4° C. IRS-1 substrate for the IR 
kinase assays was pre-phosphorylated in the absence of (y32P)-ATP using either GST- 
p85 or GST-SHP2sh2 affinity isolated kinase as described in Kinase Assays. 
Phosphorylated IRS-1 was then isolated from the solid phase bound kinases by 
filtration. IR kinase assays were then performed in a reaction buffer containing 5 pg/ml 
IRS-1, 1 pM insulin, 2.5 mM MgCI2, 7.5 mM MnCI2, 10 pM ATP, 0.1 % Triton X-100, 50 
mM Tris, pH 7.4 at RT for 15 minute with either 10 pM (y32P)-ATP (50 pCi/nmol) or 10 
pM ATP as indicated. Reactions were terminated using SDS-PAGE load buffer. 
Phosphoproteins were resolved by SDS-PAGE under reducing conditions on 7-20% 
gradient gels and examined by either autoradiography or Western analysis with anti-pY 
antibody as indicated.
Western Analysis- Western blotting was performed as previously described (31). 
In brief, proteins were resolved by SDS-PAGE on 7-20% gradient gels, electro­
transferred to PVDF and probed with the antiserum indicated. Immunoreactive proteins
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were visualized by secondary detection with [125l]-goat anti-rabbit antibody and 
autoradiography.
R esu lts
PI 3-kinase not SHP2 or IRS-1 associates with a wortmannin insensitive serine 
kinase- We have shown that PI 3-kinase associates with a serine kinase that is distinct 
form PI 3-kinase serine kinase (31). To determine if SHP2 and/or IRS-1 associate with 
a serine kinase, kinase assays were performed on SHP2, IRS-1 and PI 3-kinase 
immune complexes isolated from myeloma cells after the immune complexes were 
treated with 5 pM wortmannin. Figure 3.1A shows that SHP2 and IRS-1 
immunoprecipitates contained 5-fold less myelin basic protein (MBP) kinase activity 
than PI 3-kinase immune complexes. The kinase activity associated with SHP2 and 
IRS-1 was no greater than isotype matched control immunoprecipitates (data not 
shown). To confirm that 5 (iM wortmannin completely inhibited intrinsic PI 3-kinase 
serine kinase activity, kinase assays were performed on PI 3-kinase immune 
complexes that were either pretreated or not pretreated with 5 pM wortmannin for 30 
minute. As previously reported (31), 5 jiM wortmannin pretreatment completely 
inhibited intrinsic PI 3-kinase serine kinase activity, as indicated by a loss of p85 
phosphorylation (Figure 3.1 B). To demonstrate that the MBP phosphorylation observed 
in Figure 3.1A was due to serine residue phosphorylation, phosphoamino acid analysis 
was performed. Figure 3.1C shows that MBP was predominately phosphorylated on
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serine residues. Taken together, these results indicate that PI 3-kinase associates with 
a serine kinase (PAS kinase) that is wortmannin insensitive.
PAS kinase associates with the p85 subunit o f PI 3-kinase- The p85 subunit of 
PI 3-kinase contains protein-protein interaction sites that enable it to act as an adapter 
between itself and other proteins (15). To determine if PAS kinase associates with the 
p85 subunit of PI 3-kinase, GST fusion proteins were examined for PAS kinase binding 
capability. Figure 3.2A shows that GST-p85 affinity purifies from cell lysates a 
wortmannin insensitive serine kinase that phosphorylated MBP. This MBP kinase 
activity was 10-fold greater than that associated with glutathione-Sepharose and 8 -fold 
greater that that associated with GST. To demonstrate that the MBP phosphorylation 
observed in Figure 3.2A was due to serine residue phosphorylation, phosphoamino 
acid analysis was performed. Figure 3.2B shows that MBP was predominately 
phosphorylated on serine residues. Taken together, these findings indicate that PAS- 
kinase associates with the p85 subunit of PI 3-kinase.
PAS kinase associates with the p85 subunit o f PI 3-kinase via SH2 domain 
interactions and co-purifies with a 120 kDa tyrosine phosphorylated protein- Tyrosine 
phosphorylated peptides derived from IRS-1 sequence such as HTDDpYMPMSP 
(pY608) prevent the p85 N- and C- terminal SH2 domains from binding tyrosine 
phosphorylated proteins by competitive inhibition (17). To further delineate the 
specificity of the PAS kinase/GST-p85 interaction demonstrated in Figure 3.2, kinase 
activity isolated from cell lysates with either a GST fusion protein comprised of the first 
SH2 domain of human SHP2 (GST-SHP2SH2) or GST-p85 were analyzed. Figure 3.3A 
demonstrates that GST-p85 bound 10-fold more MBP kinase activity than GST-
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SHP2SH2and that GST-SHP2sh2 affinity isolated a similar amount of MBP kinase activity 
as GST alone. To determine if PAS kinase associates with the p85 subunit of PI 3- 
kinase via SH2 domain interactions, competitive inhibition studies were performed with 
the phosphopeptide pY608. Figure 3.3B shows that when no competing peptide is 
used GST-p85 affinity isolated 10-fold more MBP kinase activity than GST-SHP2SH2. 
Additionally, GST-Ap85 (a fusion protein comprised of GST and bovine p85 with the 
p110 binding domain deleted (32) bound similar PAS kinase activity as GST-p85, 
indicating that the p110 binding domain was not necessary for PAS-kinase/PI 3-kinase 
interactions. When 100 }iM pY608 was added to the cell lysates prior to GST fusion 
protein affinity chromatography, binding of PAS kinase to GST-p85 and GST-Ap85 was 
completely blocked. Addition of 100 pM Y608 (non-phosphorylated HTDDYMPMSP) to 
cell lysates did not alter PAS kinase binding to either GST-p85 or GST-Ap85. It should 
be noted that the SH2 domains of p85 and the first SH2 domain of SHP2 recognize 
different amino acids immediately adjacent to phosphotyrosine (36). The first SH2 
domain of SHP2 preferentially recognizes pY-IA/-X-IA//L/P motifs while the SH2 
domains of p85 preferentially recognize pYXXM (17,36,37). To confirm that both GST- 
p85 and GST-SHP2SH2 had intact SH2 domains, IRS-1 binding experiments were 
performed. Recombinant IRS-1 was phosphorylated with affinity purified IRs in the 
presence of [y32P]-ATP and incubated with equivalent amounts of GST-p85 and GST- 
SHP2SH2. Figure 3.3C demonstrates that GST-p85 and GST-SHP2SH2 bound similar 
amounts of IRS-1. To analyze the specificity of the PAS kinase/p85 interaction, PAS 
kinase binding to the N-terminal SH2 (NSH2) domain of p85 was examined. Figure
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3.3D shows that GST-p85NSH2 affinity purified 9-fold more MBP kinase activity than 
GST-SHP2SH2 and that pY608 competition completely abrogated this response. To 
further characterize the PAS kinase/p85 interaction, GST-p85 affinity purified cell 
lysates were examined by Western analysis in anti-phosphotyrosine blots. Figure 3.3E 
shows that GST-p85 affinity purified from cell lysates a 120 kDa phosphotyrosine 
containing protein (pp120). Competitive binding studies with 100 jiM pY608 and Y608 
demonstrated that pY608 completely blocked pp120 from binding GST-p85 while Y608 
had no effect. Additionally, pp120 was not immunoreactive with IRS-1 and IRS-2 
antibodies by Western analysis (data not shown). Taken together, these findings 
indicate that PAS kinase associates with the p85 subunit of PI 3-kinase via SH2 domain 
interactions and specifically reacts with the N-terminal SH2 domain of p85 when 
compared to the first SH2 domain of SHP2. Additionally, PAS kinase co-purifies with a 
pp120 kDa phosphotyrosine containing protein that associates with the p85 in an SH2 
domain dependent manner suggesting that pp120 may function as an adapter protein 
between PAS kinase and PI 3-kinase.
PAS kinase phosphorylates IRS-1 in PI 3-kinase/IRS-1 complexes- Insulin, IL-4 
and interferon-a induce PI3-kinase/IRS-1 association and serine phosphorylation of 
IRS-1 and -2 (1,2,38,39). To determine if PAS kinase phosphorylates IRS-1, kinase 
assays were performed using IRS-1 as a substrate. Figure 3.4A shows that PAS 
kinase isolated from cell lysates with GST-p85 phosphorylated IRS-1 5-fold more than 
control isolates. Additionally, IRS-1 phosphorylation by PAS kinase was completely 
inhibited when pY608 was used to competitively inhibit PAS kinase binding to GST-p85.
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To determine if the IRS-1 phosphorylation observed in Figure 3.4A was due to serine 
residue phosphorylation, phosphoamino acid analysis was performed. Figure 3.4B 
demonstrates that IRS-1 was predominately phosphorylated on serine residues. To 
determine if PAS kinase phosphorylates IRS-1 in PI 3-kinase/IRS-1 complexes, kinase 
assays were performed on PI 3-kinase immunoprecipitates isolated from cells treated 
with or without 10 nM insulin for 5 minute. Figure 3.4C demonstrates that after insulin 
stimulation IRS-1 was phosphorylated in PI 3-kinase/IRS-1 complexes by PAS kinase, 
and that this phosphorylation was predominately on serine residues (Figure 3.4D). To 
confirm that IRS-1 did not bring a serine kinase into the PI 3-kinase/IRS-1 complex, 
kinase assays utilizing MBP as a substrate were performed on PI 3-kinase 
immunoprecipitates isolated from insulin treated cells. Figure 3.4E demonstrates that 
PI 3-kinase immune complexes had identical MBP phosphorylation before and after 
insulin treatment. Taken together, these findings suggest that after insulin stimulation 
PAS kinase phosphorylates IRS-1 in PI 3-kinase/IRS-1 complexes.
PAS kinase phosphorylates IRS-1 on peptides that are phosphorylated in vivo in 
insulin treated cells- As shown in Figure 3.4, PAS kinase phosphorylates IRS-1 in vitro. 
To determine if the serine/threonine residues on IRS-1 which PAS kinase 
phosphorylates are comparable to those phosphorylated in vivo after insulin 
stimulatation, phosphopeptide mapping was performed. Figure 3.5 demonstrates that 
IRS-1 phosphorylated by PAS kinase and digested in-gel with V8 protease generated 
three phosphopeptides with molecular weights of 32 kDa, 26 kDa and 16 kDa. In-gel 
proteolysis of IRS-1 isolated from insulin treated cells generated 7 phosphopeptides 
with molecular weights of 40 kDa, 32 kDa, 26 kDa, 21 kDa, 20 kDa, 18 kDa and 16
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kDa. Comparison of these two phosphopetide maps shows that IRS-1 phosphorylated 
by PAS kinase shared three phosphopeptides (ppt) with IRS-1 isolated from insulin 
treated cells, ppt32 kDa, ppt28 kDa and ppt16 kDa. In addition, alkaline hydrolysis of 
these phosphopeptides resulted in complete loss of phosphorylation (data not shown) 
consistent with their being predominantly phosphorylated on serine/threonine residues. 
Taken together, these results indicate that PAS kinase phosphorylates IRS-1 on 
serine/threonine residues that are phosphorylated in insulin treated whole cells.
Phosphorylation of IRS-1 by PAS-kinase reduces IRS-1 phosphorylation by the 
IR- Serine phosphorylation of IRS-1 by glycogen synthase kinase-3 (GSK-3) (40) and 
mitogen activated protein kinases (MAP kinases) (41) reduces the ability of IRS-1 to act 
as an IR substrate. To determine if phosphorylation of IRS-1 by PAS kinase reduces 
IR-dependent phosphorylation of IRS-1, IR kinase assays were performed on IRS-1 
that had been pre-phosphorylated by PAS kinase. Figure 3.6A shows that IR- 
dependent phosphorylation of IRS-1 was reduced 4-fold when IRS-1 was pre- 
phosphorylated by GST-p85 affinity purified PAS kinase when compared to control 
isolates. To confirm that this effect was not due to a contaminating tyrosine kinase in 
the PAS kinase preparations, the above experiments were repeated in the absence of 
[y32P]-ATP and analyzed by Western with anti-pY antibody detection. Figure 3.6B 
demonstrates that the effects observed in Figure 3.6A were not due to pre- 
phosphorylation of IRS-1 on tyrosine residues by a contaminating tyrosine kinase. 
Taken together, these results indicate that PAS kinase is an IRS-1 serine kinase that 
decreases the ability of IRS-1 to serve as an IR substrate.
79
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
D is c u s s io n
These data establish that PI 3-kinase associates with a serine kinase (PAS 
kinase) that phosphorylates IRS-1 and reduces the ability of IRS-1 to serve as an IR 
substrate. Serine kinase assays demonstrated that PI 3-kinase co-immunoprecipitates 
with a serine kinase distinct from PI 3-kinase serine kinase (Figure 3.1). This PAS 
kinase activity was associated with the p85 subunit of PI 3-kinase (Figure 3.2), required 
SH2 domain interactions for its association with the p85 (Figure 3.3A-D) and co-purified 
with a 120 kDa tyrosine phosphoprotein that was itself dependent upon SH2 domain 
interactions in its binding to the p85 (Figure 3.3E). PAS kinase used IRS-1 as a 
substrate (Figure 3.4A,B), phosphorylated IRS-1 in PI 3-kinase/IRS-1 complexes after 
insulin stimulation (Figure 3.4C-E) and phosphorylated IRS-1 on serine/threonine 
residues comparable to those phosphorylated in insulin treated whole cells (Figure 3.5). 
More importantly, PAS kinase-dependent phosphorylation of IRS-1 inhibited 
subsequent IR-dependent phosphorylation of IRS-1 (Figure 3.6). Taken together, the 
present results indicate that PAS kinase is a novel PI 3-kinase associated IRS-1 serine 
kinase and suggest that it regulates IRS-1 serine phosphorylation after PI 3-kinase/IRS- 
1 association.
SH2 domains mediate protein-protein interactions through their ability to bind to 
phosphotyrosine residues (37). These domains have specificity and can discriminate 
between phosphotyrosines based on the three amino acids C-terminal to the 
phosphotyrosine (36). The first SH2 domain of SHP2 recognizes phosphorylated 
tyrosine (pY) in the context of pY-IA/-X-IA//L/P while the SH2 domains of PI 3-kinase 
recognize phosphorylated tyrosine in the context of pY-X-X-M (17,36,37). SH2
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domains have little affinity for non-phosphorylated tyrosine or phosphorylated tyrosine 
in motifs that lack the appropriate C-terminal amino acids (37). PAS kinase associates 
with PI 3-kinase through SH2 interactions with the p85 subunit. Association of PAS 
kinase with the p85 displays SH2 domain specificity in that PAS kinase does not bind to 
the first SH2 domain of SHP2 but does bind to the N-terminal SH2 domain of PI 3- 
kinase. In addition, PAS kinase co-purifies with a 120 kDa tyrosine phosphorylated 
protein (pp120) that associates with the p85 in an SH2 domain dependent manner. 
This result is not surprising in that PI 3-kinase has been observed to associate with a 
variety of unidentified tyrosine phosphorylated proteins with molecular weights ranging 
from 115 kDa-130 kDa (5,42-44) and a pp120 can be affinity purified from unstimulated 
FDMAC11/4.5 cells with a p85 NSH2 domain (43). Previously we have shown that PI 
3-kinase associates with a wortmannin insensitive serine kinase and that this kinase is 
not demonstrably phosphorylated on tyrosine residues (31). Therefore, our current 
model for the PAS kinase/p85 interaction is one in which pp120 serves as an adapter 
protein linking PAS kinase to the p85 subunit of PI 3-kinase.
Serine phosphorylation of IRS-1 reduces its ability to serve as an IR substrate 
and may be critical to TNF-a-dependent insulin resistance (24-30,40,41). Recent 
efforts to identify the kinases responsible for IRS-1 serine phosphorylation have 
focused on the ERK1/2 MAP kinases, since IRS-1 contains consensus sites for MAP 
kinase phosphorylation (2) and certain MAP kinase family members can be activated by 
okadaic acid, a potent effector of IRS-1 serine phosphorylation (24,45,46). 
Interestingly, phorbol esters induce Erk1/2 mediated phosphorylation of IRS-1 on Ser
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612 and lead to a subsequent decrease in IR-dependent tyrosine phosphorylation of 
IRS-1 (25, 41), but inhibition of MAP kinase activity does not block okadaic acid- 
dependent IRS-1 serine phosphorylation (45). Additionally, while replacement of IRS-1 
serine residues 612/632 with alanine leads to increased insulin-dependent tyrosine 
phosphorylation of IRS-1 and increased PI 3-kinase/IRS-1 association, replacement of 
these residues has no effect on okadaic acid-dependent IRS-1 serine phosphorylation 
(45). Moreover, MAP kinase does not appear to play a role in the serine 
phosphorylation of IRS-1 secondary to chronic insulin stimulation (47). Thus, other 
kinases must be involved in IRS-1 serine phosphorylation. Another potential IRS-1 
serine kinase is PI 3-kinase. PI 3-kinase is a dual specificity lipid and serine kinase that 
can phosphorylate its own p85 subunit and IRS-1 in vitro (19-23). Studies to date, 
however, have not clearly demonstrated that PI 3-kinase has biologically significant 
serine kinase activity in vivo. Recently, GSK-3 has been shown to phosphorylate IRS-1 
in CHO-IR cells engineered to co-express GSK-3 and IRS-1. In addition, these cells 
show a decrease in IR-mediated IRS-1 tyrosine phosphorylation (40). Since insulin 
stimulation inactivates GSK-3 (48), regulation of IRS-1 serine phosphorylation by GSK- 
3 may serve as a feed-forward step in the insulin signaling cascade. Finally, evidence 
is accumulating to suggest that serine phosphorylation within the IRS-1 IH2PTB domain 
may counter-regulate IRS-1 signaling. Recent studies have shown that the IRS-1 
docking protein 14-3-3 binds to phosphoserine 270 blocking insulin-dependent tyrosine 
phosphorylation of IRS-1 and insulin-dependent PI 3-kinase/IRS-1 association (49,50). 
Furthermore, okadaic acid and TNFa reduce the ability of IRS-1 to interact with the IR
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NPEY motif (28) which is thought to coordinate the association of the IR with the IH2PTB 
(13). In summary, we have shown previously that PI 3-kinase associates with a serine 
kinase distinct from its own intrinsic serine kinase (31). Here we report that this kinase 
is capable of phosphorylating IRS-1 and that it phosphorylates IRS-1 in PI 3- 
kinase/IRS-1 complexes after insulin stimulation. Since insulin treatment of cells 
induces serine phosphorylation of IRS-1 (2), we suggest that PAS kinase may be 
involved in this process. We conclude from this study that PI 3-kinase associates with a 
wortmannin insensitive IRS-1 serine kinase, that this kinase phosphorylates IRS-1 in PI 
3-kinase/IRS-1 complexes after insulin stimulation and decrease the ability of IRS-1 to 
serve as an IR substrate. Together, these finding suggest that PAS kinase may 
modulate IRS-1 dependent signal transduction through serine phosphorylation of IRS-1.
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Figure 3.1: PI 3-kinase not SHP2 or IRS-1 associates with a wortmannin 
insensitive serine kinase.
A, PI 3-kinase (PI3K), SHP2 (SHP2) and IRS-1 (IRS-1) immunoprecipitates were 
pretreated with 5 pM wortmannin and kinase assays were performed with these 
preparations using MBP (50 |ig/ml) as a substrate. B, PI 3-kinase immunoprecipitates 
were treated with (+) or without (-) 5 pM wortmannin (Wort) for 30 minute and then used 
in kinase assays. C, Phosphoamino acid analysis was performed on MBP 
phosphorylated by PI 3-kinase immunoprecipitates. All data are representative of 
triplicate experiments.
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Figure 3.2: PAS kinase associates with the p85 subunit of PI 3-kinase.
A, Glutathione-Sepharose bound GST-p85 (p85), GST (GST) and glutathione- 
Sepharose (Con) were incubated with or without cell lysates, as indicated. Kinase 
assays using MBP (50 pg/ml) as a substrate were performed with these preparations 
after treatment with 5 fiM wortmannin. B, Phosphoamino acid analysis was performed 
on MBP phosphorylated by GST-p85. All data are representative of triplicate 
experiments.
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Figure 3.3: PAS kinase associates with the p85 subunit of PI 3-kinase via SH2 
domain interactions and co-purifies with a 120 kDa tyrosine phosphorylated 
protein.
A, Glutathione-Sepharose bound GST-p85 (p85), GST-SHP2SH2 (SHP) and GST (GST) 
were incubated with cell lysates. Serine kinase assays using MBP (50 pg/ml) as a substrate were 
performed with these preparations after treatment with 5 pM wortmannin. 8 , Glutathione- 
Sepharose bound GST-Ap85 (A85), GST-p85 (p85) and GST-SHP2SH2 (SHP) were 
incubated with cell lysates containing either 100 pM Y608, 100 pM pY608 or no 
peptide. Serine kinase assays using MBP (50 pg/ml) as a substrate were performed on 
these preparations after treatment with 5 pM wortmannin. C, Glutathione-Sepharose 
bound GST-p85 (p85) and GST-SHP2SN2 (SHP) were incubated with 32P labeled IRS-1. 
D, Glutathione-Sepharose bound GST-p85NSH2 (NSH) and GST-SHP2SH2 (SHP) were 
incubated with cell lysates containing either 100 pM Y608, 100 pM pY608 or no 
peptide. E, Glutathione-Sepharose bound GST-p85 was incubated with or without cell 
lysates and/or 100 pM Y608 or pY608 as indicated. Phosphoproteins were detected by 
Western analysis with anti-phosphotyrosine antibody. All data are representative of 
triplicate experiments.
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Figure 3.4: PAS kinase phosphorylates IRS-1 in PI 3-kinase/IRS-1 complexes.
A, Glutathione-Sepharose bound GST-p85 (p85), GST-SHP2SH2 (SHP) and GST 
were incubated with or without cell lysates containing pY608 as indicated. Kinase 
assays using IRS-1 (5 |ig/ml) as a substrate were performed on these preparations 
after treatment with 5 i^M wortmannin. B, Phosphoamino acid analysis was performed 
on IRS-1 phosphorylated by GST-p85. C, PI 3-kinase was immunoprecipitated from 
cells treated with (+) or without (-) 10 nM insulin for 5 minute. Kinase assays were 
performed on these preparations after treatment with 5 jaM wortmannin. D, 
Phosphoamino acid analysis was performed on IRS-1 phosphorylated in p85/IRS-1 
complexes. E, Experiments were performed as in C except MBP was used as a 
substrate. All data are representative of triplicate experiments.
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Figure 3.5: PAS kinase phosphorylates IRS-1 on peptides that are phosphorylated 
in vivo in insulin treated cells.
IRS-1 was phosphorylated either in the cell by metabolic labeling with 32P, and 
insulin treatment (Whole Cell) or by kinase assays with GST-p85 affinity purified PAS 
kinase (PAS Kinase). In-gel proteolysis of phosphorylated IRS-1 was performed with 
(+) or without (-) 0.5 units of S. aureus V8 protease for 15 minute at RT. Data are 
representative of triplicate experiments.
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Figure 3.6: Phosphorylation of IRS-1 by PAS kinase reduces IRS-1
phosphorylation by the IR.
A, Glutathione-Sepharose bound GST-p85 (p85) and GST-SHP2SH2 (SHP) were 
incubated with cell lysates. These preparations were used to pre-phosphorylate IRS-1 
(5 pg/ml, no [y32P)]-ATP) after treatment with 5 pM wortmannin. IRS-1 was recovered 
from these pre-phosphorylation reactions and used in IR kinase assays. B, IRS-1 pre­
phosphorylation and IR kinases assays were performed as in A in the absence of (y32P)- 
ATP. IRS-1 and IR phosphorylation were detected by anti-phosphotyrosine blotting. All 
data are representative of triplicate experiments.
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C h ap ter 4: Insulin R ecepto r S u b s tra te -1  Serine P h osph o ry la tio n  
Induced b y  Okadaic Acid and Hyperinsulinemia Reduces th e  A b ility  of  
Insulin R e c e p to r S u b s tra te  -1 to  A c t  as a  S u b s tra te  f o r  Janus  
Kinases
A b str ac t
Serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been shown to 
reduce its ability to act AS a substrate for the insulin receptor (IR) tyrosine kinase. Here 
we report that IRS-1 serine phosphorylation induced by both okadaic acid (OA) and 
chronic insulin stimulation inhibits its subsequent tyrosine phosphorylation by interferon 
a (IFNa) activated Janus kinases (JAKs). We found that OA treatment of cells reduced 
IRS-1 stimulated phosphatidylinositol 3’-kinase (PI 3-kinase) activity by 10 fold and that 
this effect correlated with decreased IRS-1 tyrosine phosphorylation and decreased 
association between IRS-1 and the p85 subunit of PI 3-kinase. OA did not change 
IFNa activation of JAK1, but did increase IRS-1 serine phosphorylation by 4 fold. 
Moreover, IRS-1 prepared from OA treated cells was phosphorylated 4-fold less than 
IRS-1 from control cells by JAK1 in kinase assays. To further investigate the effects of 
IRS-1 serine phosphorylation on JAK mediated signaling we determined whether 
chronic hyperinsulinemia would similarly affect JAK1 mediated IRS-1 tyrosine 
phosphorylation. Treatment of cells with 1 nM insulin for 20 hours reduced IRS-1 
stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity by 2.1 fold. This effect 
correlated with decreased IRS-1 tyrosine phosphorylation and decreased association
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between IRS-1 and the p85 subunit of PI 3-kinase. We have recently shown that a PI 
3-kinase associated serine (PAS) kinase can serine phosphorylate IRS-1 after insulin 
stimulation and reduce the ability of IRS-1 to act as an IR substrate. Therefore, we also 
investigated whether PAS kinase from chronic hyperinsulinemic cells could regulate 
JAK1 mediated IRS-1 tyrosine phosphorylation. PAS kinase purified from cells treated 
with 1 nM insulin for 20 hours phosphorylated a recombinant IRS-1 protein comprised 
of amino acids 511-772 (IRS-1511 772) and reduced JAK1 mediated tyrosine 
phosphorylation of IRS-1511'772 by 3 fold. Taken together, these data indicate that IRS-1 
serine phosphorylation can decrease its JAK dependent tyrosine phosphorylation and 
that this effect can be mediated by PAS kinase.
In t r o d u c t io n
Insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation is a feature shared 
by the signal transduction pathways of a increasing number of growth factors and 
cytokines (1). Although IRS-1 tyrosine phosphorylation was originally reported in insulin 
stimulated Fao hepatoma cells (2), further studies have demonstrated that IGF-1, IL-2, 
IL-4, IL-10, IL-15, growth hormone, leukemia inhibitory factor and oncostatin M all 
stimulate IRS-1 tyrosine phosphorylation in response to receptor/ligand binding (3-6). 
Recently, type I interferons (IFNs) have also been shown to stimulate IRS-1 tyrosine 
phosphorylation (7-9). The type I IFNs are comprised of a,p and w subtypes, all of 
which activate the same IFN receptor (IFNaR) (10). While the IR is a ligand activated 
tyrosine kinase, the IFNaR lacks intrinsic tyrosine kinase activity. Instead, type I IFN
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binding induces receptor oligamerization and activation of the JAK1 and Tyk2 members 
of the Janus kinase (JAK) family of receptor associated tyrosine kinases (11-17). Type 
I IFN activated JAK1 and Tyk2 promote tyrosine phosphorylation of the IFNaR, as well 
as IRS-1, IRS-2, STAT1, STAT2, and STAT3 (6,18).
Tyrosine phosphorylated IRS-1 coordinates the intracellular actions of hormones 
and cytokines by binding to SH2 domain-containing proteins (1). The association of 
phosphatidylinositol 3' kinase (PI 3-kinase) with IRS-1 is perhaps the best 
characterized SH2/domain IRS-1 interaction. PI 3-kinase is a heterodimeric protein 
composed of a regulatory 85 kDa subunit (p85) and a catalytic 110 kDa subunit (p110) 
(19). The p85 contains N- and C- terminal SH2 domains that bind to tyrosine 
phosphorylated IRS-1 and induce PI 3-kinase activation (20,21). The p110
phosphorylates phosphoinositides on the D-3 position of the inositol ring generating 
3,4-bis and 3,4,5-tris phosphates (22,23). In the IFNaR signal transduction, PI 3-kinase 
is recruited/activated by tyrosine phosphorylated IRS-1, IRS-2 and STAT3 (7-9,24). 
The function of IFNaR activated PI 3-kinase is unclear, but inhibition of PI 3-kinase 
activity with wortmannin leads to decreased STAT3 serine phosphorylation and 
decreased transcriptional activation of IFNa activated genes (24).
In addition to being phosphorylated on tyrosine residues, IRS-1 is also 
phosphorylated on serine residues basally and in response to hormone/cytokine 
stimulation (3,4,25-28). In IR signaling, IRS-1 serine phosphorylation is thought to play 
a counter-regulatory role. Treatment of 3T3-L1 adipocytes with the serine phosphatase 
inhibitor okadaic acid (OA) results in increased IRS-1 serine phosphorylation, reduced
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IRS-1/insulin receptor binding and decreased insulin receptor-dependent tyrosine 
phosphorylation of IRS-1 (26). Similarly, IRS-1 serine phosphorylation induced by 
phorbol esters, TNF-a, PDGF, angiotensin II and insulin reduces subsequent insulin 
receptor-dependent IRS-1 tyrosine phosphorylation and PI 3-kinase/IRS-1 association 
(27-34). We have recently shown that the p85 subunit of PI 3-kinase associates with a 
novel serine kinase (PAS kinase) that can serine phosphorylate IRS-1 and reduce its 
ability to act as an IR substrate (35). However, while both IL-4 and IFNa have been 
shown to stimulate serine as well as tyrosine phosphorylation of IRS-1 (1,3,4,25), it is 
not known whether IRS-1 serine phosphorylation affects JAK mediated signaling. Here, 
we show that OA induced IRS-1 serine phosphorylation reduces its ability to act as a 
substrate for IFNa stimulated JAK1. Additionally, we demonstrate that 
hyperinsulinemia induced IRS-1 serine phosphorylation, possibly by PAS kinase, 
decreases IFNa mediated IRS-1 tyrosine phosphorylation. These data establish IRS-1 
serine phosphorylation as a general mechanism for inhibition of IRS-1 tyrosine 
phosphorylation by both receptor and non-receptor tyrosine kinases and suggest that 
PAS kinase may be one of the counter-regulatory IRS-1 serine kinases.
M a t e r ia l s  a n d  M e t h o d s
Materials- The myeloma cell line U266 was purchased from American Type
Culture Collection (Rockville, MD). [y32p]-ATP and 32pj were purchased from
Amersham (Arlington Heights, IL). PI 3-kinase p85, phosphotyrosine (pY) and IRS-1 
antisera were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). JAK1
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antiserum was purchased from Pharmingen (San Diegom, CA). Neonatal bovine serum 
(NBS) was purchased from Biocell (Rancho Dominguez, CA). Protein G-Sepharose, 
glutathione-Sepharose, Precission protease and pGex6P3 vector were purchased from 
Pharmacia Biotech (Uppsala, Sweden). Recombinant human IFNa-1 was purchased 
from Intergen (Purchase, N.Y.). Polyvinylidene difluoride membrane (PVDF) was 
purchased from Bio Rad (Hercules, CA). Cellulose coated TLC plates were purchased 
from Analtech (Newark, DE). All other cell culture reagents and chemicals were 
purchased from Sigma (ST. Louis, MO). Oligonucleotide primers were purchased from 
Operon (Almeda, CA). All other molecular biology reagents and chemicals were 
purchased from Promega (Maddison, Wl).
Cell Culture- U266 cells were grown in RPMI 1640 supplemented with 10% NBS, 
2.0 g/L glucose, 100,000 units/L penicillin and 100 mg/L streptomycin. Cells were 
passaged 1:1 with fresh medium every three days. Treatment in serum-free medium 
prior to OA studies was performed by washing cells twice and re-suspending cells in 
RPMI 1640 supplemented with 0.1% BSA, 2.0 g/L glucose, 100,000 units/L penicillin 
and 100 mg/L streptomycin at 1x10® cells/ml. Insulin treatments were performed by re- 
suspending cells in RPMI 1640 supplemented with 10% NBS, 2.0 g/L glucose, 100,000 
units/L penicillin and 100 mg/L streptomycin with or without 1 nM insulin at 1x10® 
cells/ml. All cell counts were performed on a Coulter Counter ZM (Hialeah, FL).
PI 3-kinase Assays- PI 3-kinase assays were performed as previously described 
(36). In brief, cells were treated as indicated and lysed in ice cold lysis buffer (1% 
NP40, 100 mM NaCI, 50 mM NaF, 1 mM DTT, 25 mM benzamidine, 1 mM PMSF, 2
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|jg/ml aprotinin, 2 pg/ml leupeptin, 2 mM sodium orthovanadate, 250 nM okadaic acid, 
50 mM Tris, pH 7.4). Lysates were immunoprecipitated with anti-IRS-1 antibody by 
methods previously described (36). Immune complexes were washed three times in 
lysis buffer and three times in a buffer containing 100 mM NaCI, 1 mM DTT and 10 mM 
Tris, pH 7.4. Kinase reactions were initiated by the addition of 0.33 mg/ml L-a- 
phosphatidylinositol, 7.5 mM MgCI2, 0.4 mM EGTA, 0.4 mM NaP04, 7.5 pM [y32P]-ATP 
(13 pCi/nmol), and 20 mM HEPES, pH 7.1. After the 15 min incubation at RT, reactions 
were terminated by the addition of Hcl to a final concentration of 0.8 M. Phospholipids 
were extracted with 1:1 chloroform:methanol and resolved on silica gel plates by thin 
layer chromatography (TLC) in chloroform:methanol:4 M ammonium hydroxide 
(75:58:17). Results were analyzed by autoradiography on a Molecular Dynamics 
Phosphorimage system (Sunnyvale, CA).
Western Analysis- Western blotting was performed as previously described (37). 
In brief, cells were treated as indicated and lysed in ice cold lysis buffer. Cell lysates 
were immunoprecipitated with the indicated antiserum and the resultant immune 
complexes were washed four times in lysis buffer. Proteins were resolved by SDS- 
PAGE under reducing conditions on 10% gels, electro-transferred to PVDF and probed 
with the antiserum indicated. Immunoreactive proteins were visualized by secondary 
detection using an [125l]-labeled goat anti-rabbit antibody followed by autoradiography 
and densitometric scanning on a Molecular Dynamics Personal Densitometer 
(Sunnyvale, CA).
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Expression Vector Construction- The coding sequence for amino acids 511-772 
of IRS-1 was amplified from rat IRS-1 sequence (a kind gift of Morris F. White) by 
previously described methods (35) using the forward primer (5’- 
CAGGATCCGATCTGGATAACCGGTTTC-3’) and the reverse primer (5’- 
GAGAATTCGCGCTGGGTGTGCTAAAAG-3’). The 799 bp product was introduced into 
the pGex6P3 plasmid using the BamHI and EcoRI restriction sites. The construction of 
a vector designed to express the full length bovine p85a sequence as a GST fusion 
protein (GST-p85) has been previously described (35).
GST Fusion Protein Production- GST-IRS-1511-772 and GST-p85 were generated 
as previously described (38). In brief, protein expression was induced in E. coli strain 
BL21 by the addition of isopropyl p-D-thiogalactopyranoside to a final concentration of 1 
mM. After 1 hour, bacteria were lysed in 1% Triton X-100, 1 mM PMSF, 10 mM DTT, 
140 mM NaCI, 2.7 mM KCI, 10 mM Na2 HP0 4, 1.8 mM KH2PO4 , pH 7.4 by mild 
sonication at 4° C. GST fusion proteins were affinity purified from clarified lysates using 
glutathione-Sepharose. GST- IRS-1511'772 was digested with Precission protease to 
remove IRS-1511 772 from the GST tag.
JAK Kinase Assays- JAK1 immunoprecipitates from cell lysates were washed 
four times in lysis buffer and once in CFR buffer (7.5 mM MgCI2, 2.5 mM MnCI2, 20 pM 
[y32P]-ATP (10 pCi/nmol), 20 mM HEPES, PH 7.5 at RT). Kinase reactions were 
performed in CRF buffer for 20 min at 37° C with 5 pg/ml IRS-1511'772, eluted IRS-1 or no 
substrate, as indicated. In reactions using IRS-1 prepared from cells, IRS-1 was 
immunoprecipitated from cell lysates, eluted into a buffer containing 100 mM DTT, 0.5%
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SDS, 1 mg/ml BSA and 20 mM HEPES, pH 7.4 and used in reactions at a 1:10 dilution. 
Kinase reactions were terminated by addition of SDS-PAGE load buffer and 
phosphoproteins were resolved by SDS-PAGE under reducing conditions on 7-20% 
gradient gels. Serine and threonine phosphoamino acids were removed by base 
hydrolysis (39) and the resultant tyrosine phosphoproteins were examined by 
autoradiography and densitometry.
Whole cell phosphorylation- Whole cell phosphorylation studies were performed 
by methods previously described (37). U266 cells were serum deprived overnight in 
RPMI 1640 supplemented with 0.1% BSA, re-suspended in phosphate-free RPMI 1640 
supplemented with 20 mM HEPES, pH 7.4 containing 0.75 mCi/ml 32P, for 1.5 hours at 
37° C and then treated with 1 j*M OA for 30 minutes. Cell lysates were 
immuoprecipitated with anti-IRS-1 antibody and resultant immune complexes were 
washed four times in lysis buffer. Phosphoproteins were resolved by SDS-PAGE under 
reducing conditions on 8% gels and examined by autoradiography followed by 
densitometry (Sunnyvale, CA).
Phosphoamino Acid Analysis- Phosphoamino acid analysis was performed as 
previously described (37). In brief, phosphoproteins were resolved by SDS-PAGE 
under reducing conditions on 7-20% gradient gels and electro-transferred to PVDF. 
Bands of interest were excised and acid hydrolyzed in 6 N constant boiling HCI for 2 h 
at 110° C. Samples were treated with 3 cycles of water re-suspension and evaporation 
then re-suspended in H2 0 :acetic acid.pyridine (89:10:1) running buffer containing 0.3 
mg/ml phosphoserine, phosphothreonine and phosphotyrosine standards.
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Phosphoamino acids were separated on cellulose coated plates by high voltage TLC 
and standards visualized with ninhydrine. Results were analyzed by autoradiography 
on a Molecular Dynamics Phosphorimage system (Sunnyvale, CA).
PAS Kinase Phosphorylation of IRS-1511'772- PAS Kinase assays were performed 
as previously described (35). In brief, PAS kinase was purified from lysates of cells 
treated with 1 nM insulin for 20 hours by affinity chromatography using glutathione- 
Sepharose bound GST-p85 protein. Affinity isolates were washed extensively and 
treated with 5 pM wortmannin for 30 min at 4° C. Kinase reactions were performed in a 
reaction buffer containing 5 |ig/ml IRS-1511'772, 0.4 mM EGTA, 0.4 mM NaP04, 10 mM 
MgCI2 and 20 mM HEPES, pH 7.1 at RT with or without 1 jiM [y32P]-ATP (100 
pCi/nmol), as indicated. Reactions were terminated after 5 minutes by addition of SDS- 
PAGE load buffer. Phosphoproteins resolved by SDS-PAGE under reducing conditions 
on 7-20% gradient gels and examined by autoradiography and densitometry. For PAS 
kinase pre-phosphorylation prior to JAK1 phosphorylation, IRS-1511'772 was 
phosphorylated as above except in the presence or absence of 1pM ATP, recovered by 
filtration and then used in JAK kinase assays.
R e s u l t s
OA reduces the ability o f IFNa to stimulate tyrosine phosphorylation o f IRS-1- 
OA treatment of 3T33-L1 adipocytes reduces IR mediated IRS-1 tyrosine 
phosphorylation and PI 3-kinase association (26). To investigate whether OA regulates 
IFNa mediated IRS-1 signaling, cells were incubated in the presence or absence of 1 p
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M OA for 30 minutes and stimulated with 1000 u/ml IFNa for the times indicated. IRS-1 
was immunoprecipitated from cell lysates and PI 3-kinase assays were performed. 
Figure 4.1 A shows that OA reduced the ability of IFNa to stimulate IRS-1 associated PI 
3-kinase activity by 10 fold. To confirm that the decrease in IRS-1 associated PI 3- 
kinase activity was due to a decrease in IRS-1/PI 3-kinase association rather than a 
decrease in whole cell PI 3-kinase activity, western blot analysis was performed. Figure 
4.1B demonstrates that the reduction in IRS-1 associated PI 3-kinase activity correlated 
with a reduction in the association of IRS-1 with the p85 subunit of PI 3-kinase. In 
addition, OA had no effect on constitutive PI 3-kinase activity as measured in PI 3- 
kinase immunoprecipitates (data not shown). To determine if the decreased ability of 
IRS-1 to recruit/activate PI 3-kinase was due to a decrease in IRS-1 tyrosine 
phosphorylation, western blot analysis was performed. Figure 4.1C shows that the 
reduction in IRS-1 recruitment/activation of PI 3-kinase was paralleled by a decrease in 
IRS-1 tyrosine phosphorylation. Finally, western blot analysis was used to verify that 
OA did not alter total cellular levels of IRS-1, p85 and Jak1 proteins (Figure 4.1D). It 
should be noted that to facilitate analysis, the gels for IRS-1/IRS-1 western blots were 
run for a shorter time to minimize OA mediated shifting/diffusing of the IRS-1 protein 
band (see Figure 4.3A). Taken together, these results indicate that OA counter- 
regulates IFNa signaling by reducing IRS-1 tyrosine phosphorylation and IRS-1/PI 3- 
kinase association.
IFNa activates JAK1 after OA treatment and JAK1 from OA-treated cells 
phosphorylates IRS-1- IFNa fails to stimulate IRS-1 tyrosine phosphorylation in cells
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that lack JAK1 activity (13). To determine whether OA reduces IFNa mediated IRS-1 
phosphorylation by reducing JAK1 activity, kinase assays were performed. JAK1 was 
immunoprecipitated from cells after stimulation with 1000 u/ml IFNa for the indicated 
times and subjected to kinase assays. Phosphoproteins were resolved by SDS-PAGE 
under reducing conditions and subjected to in gel alkaline hydrolysis to remove 
serine/threonine phosphoamino acids (39). Figure 4.2A shows that JAK1 auto-kinase 
activity remained stabile from 1 to 10 min following IFNa stimulation. Therefore, JAK1 
auto-kinase activity was assessed after 5 min IFNa (1000 u/ml) stimulation in cells that 
had been pretreated with or without 1 pM OA. Figure 4.2B demonstrates that JAK1 
prepared from OA-treated cells had similar auto-kinase activity as JAK1 prepared from 
control cells. In addition, western blot analysis shows that IFNa stimulated JAK1 
tyrosine phosphorylation was the same in the cell treated with or without OA (Figure 
4.2C). To determine if OA alters the kinase activity of JAK1 toward exogenous 
substrates, JAK1 kinase assays were performed using IRS-1511'772 as a substrate. JAK1 
immunoprecipitates were prepared from cells after stimulation with 1000 u/ml IFNa for 
the indicated times and kinases assays were performed in the presence of 5 jig/ml IRS- 
-1511-772 Figure 4.2C shows that IRS-1511'772 phosphorylation occurred with a similar IFNa 
dependent time course as JAK1 autophosphorylation. Figure 4.2D demonstrates that 
IRS-1511'772 phosphorylation by JAK1 assessed after 5 min IFNa (1000 u/m l) stimulation 
was the same in cells that had been pretreated with or without 1 |aM OA. These results 
indicate that OA does not alter IFNa mediated IRS-1 tyrosine phosphorylation by 
directly inhibiting JAK1 kinase activity.
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OA induces IRS-1 serine phosphorylation and reduces its ability to act as a JAK1 
substrate- OA leads to IRS-1 hyperphosphorylation on serine residues in 3T3-L1 
adipocytes (26). To determine if OA leads to increased IRS-1 serine phosphorylation in 
U266 myeloma cells, whole cell phosphorylation analysis was performed. Cells were 
incubated with 32P, for 1.5 h and then treated with or without 1 pM OA for 30 min. IRS-1 
was immunoprecipitated from cell lysates and resolved by SDS-PAGE under reducing 
conditions on 8% gels. Figure 4.3A shows that OA increased IRS-1 phosphorylation by 
4 fold and also decreased its electrophoretic mobility. This shifting/diffusing of IRS-1 
has been previously observed and correlates OA induced hyperphophorylation of IRS-1 
on serine residues (26). To verify that OA increases IRS-1 phosphorylation on serine 
residues, phosphoamino acid analysis was performed on IRS-1 from whole cell 
phosphorylations in the presence and absence of OA treatment. Figure 4.3B 
demonstrates that OA increases IRS-1 phosphorylation predominately on serine 
residues. To investigate whether IRS-1 serine phosphorylation directly interferes with 
its ability to act as JAK1 substrate, IRS-1 was immunoprecipitated from cells treated 
with or without 1 pM OA. IRS-1 was eluted from immunoprecipitates and used as a 
substrate for JAK1 immunoprecipitated from cells treated with or without 1000 u/ml 
IFNa. Figure 4.3C demonstrates that IRS-1 prepared from OA treated cells was 4 fold 
less phosphorylated by IFNa activated JAK1 than IRS-1 prepared from control cells. 
These data indicate that OA induced IRS-1 serine phosphorylation inhibits subsequent 
JAK1 mediated IRS-1 tyrosine phosphorylation.
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Chronic hyperinsulinemia reduces IFNa mediated IRS-1 signaling- Chronic 
hyperinsulinemia has been shown to reduce iR mediated signaling by increasing IRS-1 
phosphorylation on serine residues (33,34,40-42). Since IRS-1 serine phosphorylation 
reduces IFNa dependent IRS-1 tyrosine phosphorylation, the ability of chronic 
hyperinsulinemia to regulate IFNa signaling was examined. To more properly evaluate 
the effects of chronic hyperinsulinemia on IFNa mediated IRS-1 signaling, these 
experiments were performed on cells without prior serum deprivation. Additionally, the 
concentration of insulin used (1 nM) reflects the serum insulin levels observed in 
hyperinsulinemic humans (43). Figure 4.4A shows that pre-treatment of cells with 1 nM 
insulin for 20 hours reduces IRS-1 associated PI 3-kinase activity by 2.1 fold. To 
confirm that the observed decrease in IRS-1 associated PI 3-kinase activity was due to 
a decrease in both IRS-1/PI 3-kinase association and IRS-1 tyrosine phosphorylation, 
western blot analysis was performed. Figure 4.4B demonstrates that treatment of cells 
with 1 nM insulin for 20 hours decreases the association of IRS-1 with the p85 subunit 
of PI 3-kinase by 2.5 fold. In addition, chronic hyperinsulinemia reduces IFNa mediated 
IRS-1 tyrosine phosphorylation by 2.6 fold. Figure 4.4C shows that hyperinsulinemia 
did not alter the total cellular levels of IRS-1, p85 and JAK1 proteins. Thus, chronic 
hyperinsulinemia reduces the ability of IFNa to stimulate IRS-1 recruitment/activation of 
PI 3-kinase and this effect correlates with a decrease in IFNa mediated IRS-1 tyrosine 
phosphorylation. To verify that chronic hyperinsulinemia does not alter IFNa mediated 
JAK1 activation, kinase assays were performed. Figure 4.4D shows that treatment of 
cells with 1 nM insulin for 20 hours did not change the ability of JAK1 to phosphorylate
113
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
IRS-1511'772. Note that since these cells were grown in serum-containing medium, JAK1 
had considerable background kinase activity. However, the IFNa mediated increase in 
IRS-1511'772 phosphorylation by JAK1 was unchanged by chronic hyperinsulinemia. 
These results indicate that chronic hyperinsulinemia reduces IRS-1 
recruitment/activation of PI 3-kinase in response to IFNa without directly changing JAK 
activation.
PAS kinase mediated IRS-1 serine phosphorylation reduces its ability to act as a 
JAK kinase substrate- Chronic hyperinsulinemia leads to increased phosphorylation on 
serine residues contained within an IRS-1 fragment comprised of amino acids 530-843 
(34) and decreased IR mediated IRS-1 tyrosine phosphorylation. In addition, we have 
recently shown that a novel, PI 3-kinase associated serine kinase (PAS kinase) can 
serine phosphorylate IRS-1 after insulin stimulation and reduce its ability to act as an IR 
substrate (35). To determine if PAS kinase purified from cells after chronic 
hyperinsulinemia treatment can induce IRS-1 serine phosphorylation and reduce the 
ability of IRS-1 to act as a substrate for JAK1, kinase assays were performed. Figure 
4.5A shows that GST-p85 bound PAS kinase phosphorylates IRS-1511'772. In gel 
alkaline hydrolysis of serine/threonine phosphoamino acids was used to verify that PAS 
kinase phosphorylates IRS-1511'772 predominately on serine residues (data not shown) 
(39). Figure 4.5B demonstrates that PAS kinase mediated IRS-1511'772 serine 
phosphorylation decreases subsequent tyrosine phosphorylation by JAK1 by 3 fold. 
These results indicate that PAS kinase purified from cells after chronic hyperinsulinemia
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treatment can serine phosphorylate IRS-1 and reduce its ability to act as a JAK kinase 
substrate and that PAS kinase may be important in regulating IFNa signaling.
D iscu ssio n
These data establish that IRS-1 serine phosphorylation reduces its ability to act 
as a JAK kinase substrate and suggest that PAS kinase could decrease JAK mediated 
IRS-1 phosphorylation in cells in response to chronic hyperinsulinemia. PI 3-kinase 
assays as well as western blot analysis demonstrate that OA reduces IFNa mediated 
IRS-1 tyrosine phosphorylation and thus impairs IRS-1 recruitment/ activation of PI 3- 
kinase in response to IFNa stimulation (Figure 4.1). This decrease was not due to a 
direct effect of OA on JAK activity, since IFNa stimulated JAK1 auto-kinase activity and 
JAK1 phosphorylation of recombinant IRS-1511'772 were not changed by OA treatment 
(Figure 4.2). However, OA stimulated IRS-1 serine phosphorylation and decreased the 
ability of IRS-1 to act as a JAK1 substrate (Figure 4.3). Chronic hyperinsulinemia also 
reduced IFNa stimulated recruitment/activation of PI 3-kinase (Figure 4.4A-C) but had 
no direct effect on IFNa stimulated JAK1 activity (Figure 4.4D). More importantly, PAS 
kinase mediated serine phosphorylation of IRS-1511'772 inhibited subsequent JAK1 
dependent tyrosine phosphorylation of IRS-1511'772 (Figure 4.5). Taken together, the 
present results indicate that IRS-1 serine phosphorylation induced by both OA and 
chronic hyperinsulinemia reduces JAK mediated IRS-1 tyrosine phosphorylation and 
suggest that during chronic hyperinsulinemia, PAS kinase may counter-regulate IRS-1 
tyrosine phosphorylation by JAKs.
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IRS-1 is serine phosphorylated in its basal state and inhibitors of type PP1 and 
PP2A PSPs such as OA and calyculin A increase this basal IRS-1 serine 
phosphorylation, leading to decreased IR mediated IRS-1 tyrosine phosphorylation 
(26,33). Similarly, PSP inhibition/PSK stimulation by TNFa leads to an increase in IRS- 
1 serine phosphorylation and a reduction in insulin stimulated IRS-1 tyrosine 
phosphorylation (27,28). IRS-1 serine phosphorylation also occurs in response to 
hormone/cytokine stimulation. Insulin, IGF-I, IL-4 and IFNa all stimulate IRS-1 serine 
phosphorylation in addition to inducing IRS-1 tyrosine phosphorylation and IRS-1/PI 3- 
kinase association (2-4,8,9,25,44). Recently, chronic hyperinsulinemia stimulated IRS- 
1 serine phosphorylation has been associated with decreased IR mediated IRS-1 
tyrosine phosphorylation and insulin resistance (33,34,40-42). The function of basal 
and hormone/cytokine stimulated IRS-1 serine phosphorylation in JAK associated 
receptor signaling had not been previously determined. Here, we demonstrate for the 
first time that OA and insulin induced IRS-1 serine phosphorylation impairs JAK 
mediated IRS-1 tyrosine phosphorylation.
One possible mechanism for the decrease in IR mediated tyrosine 
phosphorylation of serine phosphorylated IRS-1 involves the impaired NPXY binding 
capacity displayed by serine phosphorylated IRS-1 (33). In this model, serine 
phosphorylated IRS-1 fails to associate with the IR following insulin stimulation and thus 
cannot be tyrosine phosphorylated. Like insulin and IGF-I receptors, IL-4 receptors 
also contain NPXY motifs that are thought to help coordinate IRS-1/receptor complex 
association (44,45). However, other JAK associated receptors such as IFNaR and
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growth hormone receptor do not have NPXY motifs and may rely solely on 
IH1PN/receptor complex interactions to coordinate IRS-1 binding (8 ). Thus, one 
possibility is that IRS-1 serine phosphorylation may block IH1PM/receptor complex 
interactions. However, our data shows that serine phosphorylated IRS-1 is a poor in 
vitro substrate for immunoprecipitated JAK1. Moreover, the effect of serine 
phosphorylation on JAK1 is still observed with IRS-1511'772, a fragment that contains 
neither IH1PH nor IH2PTB domains. This suggests that IRS-1 serine phosphorylation may 
also block IFNa mediated IRS-1 tyrosine phosphorylation by a more direct mechanism 
that does not involve reduced IRS-1/receptor complex association.
Recently, chronic hyperinsulinemia was shown to specifically induce serine 
phosphorylation of an IRS-1 fragment comprised of amino acid residues 530-843 and 
lead to insulin resistance (34). However, the kinase responsible for this 
phosphorylation was insensitive to PKC, PKA, PI 3-kinase and MAP kinase inhibitors. 
We show here that PAS kinase isolated from cells after chronic hyperinsulinemia serine 
phosphorylates IRS-1511'772 and impairs JAK1 mediated IRS-1511'772 tyrosine 
phosphorylation. Interestingly, PAS kinase is also insensitive to PKC, PI 3-kinase and 
MAP kinase inhibitors (37). In addition, phosphopeptide mapping studies suggest that 
PAS kinase serine phosphorylates IRS-1 on residues that are phosphorylated in 
response to insulin stimulation (35). Thus, PAS kinase may also modulate IR 
dependent IRS-1 tyrosine phosphorylation following chronic hyperinsulinemia. This 
possibility is currently being investigated.
In summary, we have shown that insulin and OA induced IRS-1 serine 
phosphorylation impair JAK mediated IRS-1 tyrosine phosphorylation. Moreover, the 
effect of chronic hyperinsulinemia on JAK mediated IRS-1 tyrosine phosphorylation can
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be recapitulated in vitro using IRS-1511'772 and PAS kinase. Taken together, these 
observations indicate that IRS-1 serine phosphorylation can counter-regulate signaling 
by JAK associated receptors and suggest that PAS kinase may be involved in the 
reduction in JAK mediated IRS-1 tyrosine phosphorylation that follows chronic 
hyperinsulinemia.
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Figure 4.1: OA reduces IFNa mediated IRS-1 tyrosine phosphorylation.
A, B, C, U266 cells were serum deprived for 18 hours and treated without 
(Control) or with (OA) 1 pM OA for 30 minutes. Cells were then stimulated with 1000 
u/ml IFNa for the times indicated and cell lysates were immunoprecipitated with anti- 
IRS-1. A, PI 3-kinase assays were performed on IRS-1 immunoprecipitates. B, IRS-1 
associated proteins were resolved by SDS-PAGE under reducing conditions on 8% 
gels, transferred to PVDF and blotted with anti-phosphotyrosine. C, IRS-1 associated 
proteins were resolved by SDS-PAGE under reducing conditions on 8 % gels, 
transferred to PVDF and blotted with anti-p85. D, U266 cells were serum deprived for 
18 hours and treated without or with 1 pM OA for 30 minutes. Cell lysates were 
immunoprecipitated with anti-IRS-1, anti-p85 or anti-JAK1, as indicated. Proteins were 
resolved by SDS-PAGE under reducing conditions on 8% gels, transferred to PVDF 
and blotted with anti-IRS-1, anti-p85 or anti-JAK1, as indicated. All data are 
representative of triplicate experiments.
119
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Control OA
Time (min1 0 5 10 30 0 5 10 30
B Control 
Time (mini 0 5 10 30
p85"
0
OA 
5 10 30 IP: IRS-1 
Blot: p85
Time (min 
IRS-1-**
Control 
5 10 30
OA 
5 10 30 IP: IRS-1 
Blot: pY
D OA
+
IRS-1- LI 3
IP:
Blot:
IRS-1
IRS-1
OA OA
p85-
IP: p85 
Blot: p85
Jak l^H S
IP: JAK1 
Blot: JAK1
120
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 4.2: JAK1 prepared from OA-treated cells phosphorylates IRS-1511'772.
A, U266 cells were serum deprived for 18 hours and treated with 1000 u/ml IFNa 
for the times indicated. Cell lysates were immunoprecipitated with anti-JAK1 and 
kinase assays were performed. B, U266 cells were serum deprived for 18 hours, 
treated without or with 1 pM OA for 30 minutes and then treated with 1000 u/ml IFNa 
for 5 minutes. Cell lysates were immunoprecipitated with anti-JAK1 and kinase assays 
were performed. C, Cells were treated as in A and cell lysates were 
immunoprecipitated with anti-JAK1. Proteins were resolved by SDS-PAGE under 
reducing conditions on 8 % gels, transferred to PVDF and blotted with anti- 
phosphotyrosine. D, Cells were treated as in A, except IRS-1511'772 (5pg/ml) was used 
as a JAK1 substrate. E, Cells were treated as in B, except IRS-1511'772 (5pg/ml) was 
used as a JAK1 substrate. All data are representative of triplicate experiments.
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Figure 4.3: OA induced IRS-1 serine phosphorylation reduces subsequent JAK1
mediated IRS-1 tyrosine phosphorylation.
A, U266 cells were serum deprived for 18 hours, labeled with 32P, for 1.5 hours 
and incubated without or with 1 pM OA for 30 minutes. Cell lysates were 
immunoprecipitated with anti-IRS-1 and proteins were resolved by SDS-PAGE under 
reducing conditions on 8% gels. 8 , IRS-1 was generated as in A and subjected to 
phosphoamino acid analysis. C, IRS-1 was immunoprecipitated from lysates of cells 
that had been serum deprived for 18 hours and incubated without or with 1 pM OA for 
30 minutes. JAK1 was immunoprecipitated from lysates from cells that had been 
treated without or with 1000 u/ml IFNa for 5 minutes. IRS-1 was then eluted from 
immunoprecipitates and used in JAK1 kinase assays. All data are representative of 
triplicate experiments.
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Figure 4.4: Chronic hyperinsulinemia decreases IFNa mediated IRS-1 tyrosine
phosphorylation.
A, B, U266 cells were treated without or with 1 nM insulin for 20 hours and then 
stimulated without or with 1000 u/ml IFNa for 5 minutes. A, Cell lysates were 
immunoprecipitated with anti-IRS-1 and PI 3-kinase assays were performed. B, Cell 
lysates were immunoprecipitated with anti-IRS-1. Proteins were resolved by SDS- 
PAGE under reducing conditions on 8% gels, transferred to PVDF and blotted with 
either anti-phosphotyrosine or anti-p85, as indicated. C, U266 cells were treated 
without or with 1 nM insulin for 20 hours. Cell lysates were immunoprecipitated with 
anti-IRS-1, anti-p85 or anti-JAK1, as indicated. Proteins were resolved by SDS-PAGE 
under reducing conditions on 8 % gels, transferred to PVDF and blotted with anti-IRS-1, 
anti-p85 or anti-JAK1, as indicated. D, U266 cells were treated without or with 1 nM 
insulin for 20 hours and then stimulated without or with 1000 u/ml IFNa for 5 minutes. 
Cell lysates were immunoprecipitated with anti-JAK-1 and kinase assays were 
performed using IRS-1511'772 (5pg/ml) as a substrate. All data are representative of 
triplicate experiments.
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Figure 4.5: Phosphorylation of IRS-1511'772 by PAS kinase reduces its
phosphorylation by JAK1.
PAS kinase was purified by affinity chromatography using GST-p85 from lysates 
of U266 cells that had been treated with 1 nM insulin for 20 hours. A, After treatment 
with 5 pM wortmannin, PAS kinase preparations were used to phosphorylate IRS-1511'772 
(5 pg/ml) without (PAS kinase -) or with (PAS kinase +) 1 pM [y32P]-ATP (100 pCi/nmol). 
B, After treatment with 5 pM wortmannin, PAS kinase preparations were used to pre- 
phosphorylate IRS-1511'772 (5 pg/ml) without (PAS kinase -) or with (PAS kinase +) 1 pM 
ATP (no [y32P]-ATP). IRS-1 was recovered from these pre-phosphorylation reactions 
and used kinase assays with JAK1 immunoprecipitated from IFNa stimulated cells 
(JAK1 +). All data are representative of triplicate experiments.
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A p p e n d ix  A : C o n c lu sio n s  a n d  Future  D ir e c tio n s
The data presented in this thesis show that PI 3-kinase associates with a novel, 
OA sensitive serine kinase (PAS kinase) that is biochemically distinct from the intrinsic 
serine kinase activity of the PI 3-kinase p110 subunit. PAS kinase is an IRS-1 serine 
kinase that can reduce the ability of IRS-1 to act as an IR/IFNaR substrate. The 
association of PAS kinase with the PI 3-kinase p85 subunit requires intact SH2 
domains and correlates with the presence of a 76 kDa serine phosphoprotein (pp76) 
and a 120 kDa tyrosine phosphoprotein (pp120) in p85 affinity isolates. The current 
data suggest a model where pp120 binds the N-terminal SH2 domain of p85 and acts 
as an adaptor for pp76 serine kinase (Figure A1). Since the p110 binding domain of 
p85 is not required for this interaction and there is a substantial pool of p85 protein in 
the cell that is not complexed with p110, it is not clear whether PAS kinase with p85 
that is bound to p110, free p85 or both. Experiments where p110 is precleared from 
cell lysates by immunoprecipitated and then p85 associated PAS kinase activity is 
measured should help clarify this point. In addition, it is not clear that the PAS 
kinase/p85 association is constitutive in vivo. PAS kinase could localize to a subcellular 
compartment that does not contain p85 and then co-localize with p85 upon 
hormone/cytokine stimulation. Determining the subcellular localization of p85/p110 
complexes, free p85 protein and PAS kinase in the presence and absence of insulin 
stimulation should begin to clear up both the former and later points.
Information on the amino acid sequences of pp120 and pp76 should further 
delineate the formation of the PAS kinase pp120/pp76 complex and definitively identify
-i
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the serine kinase activity of PAS kinase. Both pp76 and pp120 bands are observed on 
silver-stained gels of proteins that are affinity isolated by the GST-p85 fusion proteins. 
N-terminal and possibly tryptic fragment amino acid sequences of these bands should 
allow the construction of PCR primers to begin isolating the cDNAs that encode 
pp120/pp76. In addition, specific antibodies generated from these peptide sequences 
could be used to further characterize pp120 and pp76.
Phosphopeptide mapping reveals that PAS kinase phosphorylates 
phosphopeptides that are serine phosphorylated in response to insulin stimulation. 
Additionally, PAS kinase phosphorylates a fragment of IRS-1 (IRS-1511'772) that appears 
to be phosphorylated specifically in response to hyperinsulinemia. Determination of the 
exact sites of IRS-1 serine phosphorylation by PAS kinase and comparison of these 
sites with those phosphorylated in response to insulin would help to more firmly 
establish IRS-1 as a counter-regulatory serine kinase. When the cDNA sequences of 
pp120 and pp76 are known, dominant negative or targeted gene knockouts could be 
used to better prove the role of PAS kinase in the biological effects of IRS-1 serine 
phosphorylation.
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Figure Al: The role of PAS kinase in IR and IFNaR signaling.
PAS kinase (pp76/ppl20) may associate constitutively with the p85 subunit of PI 3-kinase. 
Alternatively, the two may exist in separate subcellular compartments until hormone/cytokine stimulation. 
Upon hormone/cytokine stimulation PAS kinase associates with tyrosine phosphorylated IRS-1 through the 
p85 subunit of PI 3-kinase and serine phosphorylates IRS-1. PAS kinase mediated IRS-1 serine 
phosphorylation inhibits further tyrosine phosphorylation by IR/IFNaR.
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